



Review

An Exploratory Investigation of Chatbot Applications in Anxiety Management: A Focus on Personalized Interventions

Alexia Manole ¹ , Răzvan Cârciumaru ^{2,*} , Rodica Brînzaș ³ and Felicia Manole ⁴

¹ Faculty of Medicine, University of Oradea, 410087 Oradea, Romania; manole.alexia@student.uoradea.ro

² Doctoral School of Sociology, Faculty of Social and Human Sciences, University of Oradea, 410087 Oradea, Romania

³ Independent Researcher, 031046 Bucharest, Romania; brinzas.rodica@gmail.com

⁴ ENT Department, Faculty of Medicine, University of Oradea, 410087 Oradea, Romania; fmanole@uoradea.ro

* Correspondence: carciumaru.razvand@gmail.com or carciumaru.razvandacian@student.uoradea.ro

Abstract: Anxiety disorders are among the most prevalent mental health conditions globally, causing significant personal and societal burdens. Traditional therapies, while effective, often face barriers such as limited accessibility, high costs, and the stigma associated with seeking mental health care. The emergence of artificial intelligence (AI) chatbots offers a novel solution by providing accessible, cost-effective, and immediate support for individuals experiencing anxiety. This comprehensive review examines the evolution, efficacy, advantages, limitations, challenges, and future perspectives of AI chatbots in the treatment of anxiety disorders. A methodologically rigorous literature search was conducted across multiple databases, focusing on publications from 2010 to 2024 that evaluated AI chatbot interventions targeting anxiety symptoms. Empirical studies demonstrate that AI chatbots can effectively reduce anxiety symptoms by delivering therapeutic interventions like cognitive-behavioral therapy through interactive and personalized dialogues. The advantages include increased accessibility without geographical or temporal limitations, reduced costs, and an anonymity that encourages openness and reduces stigma. However, limitations persist, such as the lack of human empathy, ethical and privacy concerns related to data security, and technical challenges in understanding complex human emotions. The key challenges identified involve enhancing the emotional intelligence of chatbots, integrating them with traditional therapy, and establishing robust ethical frameworks to ensure user safety and data protection. Future research should focus on improving AI capabilities, personalization, cultural adaptation, and user engagement. In conclusion, AI chatbots represent a promising adjunct in treating anxiety disorders, offering scalable interventions that can complement traditional mental health services. Balancing technological innovation with ethical responsibility is crucial to maximize their potential benefits.

Keywords: AI chatbots; anxiety disorders; mental health interventions; cognitive-behavioral therapy; ethical challenges in AI; personalized support systems; digital health solutions



Academic Editors: Heming Jia, Antonio Jiménez-Martín and Marko Gulić

Received: 11 December 2024

Revised: 23 December 2024

Accepted: 27 December 2024

Published: 29 December 2024

Citation: Manole, A.; Cârciumaru, R.; Brînzaș, R.; Manole, F. An Exploratory Investigation of Chatbot Applications in Anxiety Management: A Focus on Personalized Interventions. *Information* **2025**, *16*, 11. <https://doi.org/10.3390/info16010011>

Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Anxiety disorders are among the most common mental health conditions worldwide, affecting people of all ages and backgrounds. The World Health Organization has identified these disorders as major contributors to the global disease burden, with an estimated 264 million individuals affected globally [1,2]. Characterized by excessive fear, worry, and related behavioral disturbances, anxiety disorders can significantly impair daily functioning

and reduce quality of life [3]. The pervasive nature of anxiety disorders underscores the need for effective and accessible treatment options [4,5].

Traditional therapeutic approaches to anxiety, such as cognitive-behavioral therapy (CBT) and pharmacotherapy, have been extensively researched and are considered effective treatments. CBT, in particular, has demonstrated substantial efficacy in helping individuals identify and modify maladaptive thought patterns and behaviors associated with anxiety [6,7]. Pharmacological interventions, including selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, are also commonly prescribed to alleviate symptoms [8]. However, despite the proven effectiveness of these treatments, numerous barriers impede access to traditional mental health services.

One of the primary barriers is the limited availability of qualified mental health professionals, especially in rural or low-income areas. The demand for mental health services often exceeds the availability of providers, leading to long wait times and overburdened healthcare systems [9]. Additionally, the high cost of therapy and medication can be prohibitive for many individuals, particularly those without adequate health insurance coverage [10]. The stigma associated with mental health issues further discourages people from seeking help, as they may fear judgment or discrimination from others [11].

The integration of technology into mental health care has emerged as a promising solution to address these barriers. Digital interventions, such as internet-based CBT programs and mobile health applications, have gained traction due to their potential to increase accessibility, reduce costs, and provide anonymity. Among these technological advancements, artificial intelligence (AI) chatbots have garnered significant attention as innovative tools for delivering mental health interventions [12–14].

AI chatbots are computer programs designed to simulate human-like conversations through natural language processing and machine learning algorithms. In the context of mental health, these chatbots can deliver therapeutic content, offer emotional support, and assist users in managing symptoms [15]. They are available 24/7, providing immediate assistance without the constraints of scheduling or geographic limitations. By leveraging AI technologies, chatbots can personalize interactions based on user inputs, adapting their responses to meet individual needs [16,17].

Recent studies have begun to explore the effectiveness of AI chatbots in managing anxiety, revealing that they can significantly reduce symptoms through interactive and personalized interventions [13]. A randomized controlled trial found that participants using a mental health chatbot reported decreased levels of generalized anxiety compared to a control group [18,19]. Furthermore, AI chatbots have been shown to improve engagement and adherence to therapeutic exercises, as their interactive nature can enhance user motivation [20].

However, integrating these chatbots into existing mental health frameworks presents both opportunities and challenges. One concern is whether chatbots can replicate the therapeutic alliance—a critical component of successful psychotherapy characterized by trust, empathy, and collaboration between therapist and client [21]. While AI chatbots can simulate empathetic responses, they may lack the genuine human connection that fosters deep therapeutic change [17]. Additionally, issues related to data privacy and security are paramount, as chatbots often collect sensitive personal information [14,22]. Ensuring compliance with ethical standards and regulations is essential to protect users [23].

The rapid advancement in AI technologies necessitates a comprehensive examination of their role in mental health interventions. This review aims to synthesize the current literature on the use of AI chatbots in anxiety treatment, focusing on their efficacy, advantages, limitations, and future directions. By critically evaluating the existing research—particularly studies published in open-access journals such as those by the Multidisciplinary

Digital Publishing Institute (MDPI), Elsevier, and Frontiers—this review seeks to provide valuable insights for clinicians, researchers, and policymakers.

This review examines the evolution, efficacy, advantages, and limitations of AI chatbots in treating anxiety disorders, aiming to synthesize the current research and guide future technological and therapeutic strategies.

The objectives of this review are as follows:

- *Assess the Efficacy of AI Chatbots in Anxiety Treatment:* Evaluate the effectiveness of AI chatbot interventions in reducing anxiety symptoms compared to traditional therapeutic approaches and control conditions;
- *Identify Advantages of AI Chatbots:* Explore the benefits of using AI chatbots for anxiety treatment, including increased accessibility, cost-effectiveness, personalization, and user engagement;
- *Examine Limitations and Challenges:* Discuss the potential drawbacks and concerns associated with AI chatbot interventions, such as limitations in empathetic interaction, ethical considerations, and technological constraints;
- *Explore Future Perspectives:* Investigate opportunities for enhancing AI chatbot interventions, including technological innovations, integration with traditional therapy, and strategies to address ethical and regulatory challenges.

By addressing these objectives, this review aims to contribute to a nuanced understanding of how AI chatbots can be effectively utilized in anxiety treatment and identify areas where further research and development are needed.

Significance of the Review

The increasing prevalence of anxiety disorders and the limitations of current mental health care systems highlight the urgent need for accessible and effective treatment modalities. AI chatbots represent a novel approach that could potentially transform the delivery of mental health services [24]. However, to fully realize their potential, it is essential to understand both their capabilities and limitations. This review provides a timely and comprehensive analysis of AI chatbots in anxiety treatment, offering evidence-based insights that can inform clinical practice, technological development, and policy formulation. Furthermore, it encompasses a broad range of studies investigating AI chatbot interventions for anxiety, including randomized controlled trials, pilot studies, and qualitative research. Emphasis is placed on open-access literature to ensure that the findings are widely accessible. The methodology involves a rigorous search of the relevant databases, critical appraisal of study quality, and synthesis of the results to draw meaningful conclusions about the current state of the field.

By integrating findings from diverse studies, this review aims to provide a holistic perspective on the use of AI chatbots in anxiety treatment. It highlights successful applications, identifies gaps in the literature, and proposes directions for future research. This review also considers the practical implications of implementing AI chatbot interventions in real-world settings, offering recommendations for clinicians and developers.

The intersection of AI technology and mental health care presents both opportunities and challenges. AI chatbots have the potential to expand access to anxiety treatment, but their efficacy and ethical use must be thoroughly evaluated. This review serves as a foundational resource for understanding the current landscape and guiding the responsible integration of AI chatbots into mental health services.

2. Materials and Methods

This review employs a rigorous approach to identify, evaluate, and synthesize the existing literature on the use of AI chatbots in the treatment of anxiety disorders. While this

review is not a systematic review, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in part to enhance the methodological rigor and transparency.

2.1. Search Strategy

A comprehensive literature search was conducted across multiple electronic databases to capture a wide range of relevant studies. The databases searched included the following:

- *PubMed/MEDLINE*: To access biomedical literature from MEDLINE, life science journals, and online books;
- *PsycINFO*: For psychology-related articles, including mental health interventions;
- *Scopus*: To include a broad spectrum of peer-reviewed literature across scientific disciplines;
- *Web of Science*: For the multidisciplinary coverage of high-impact journals;
- *MDPI*: Specifically targeted due to its open-access policy and relevant journals such as the *International Journal of Environmental Research and Public Health*;
- Elsevier and Frontiers: Fit for research because of their open-access policy.

The search was limited to articles published between January 2010 and October 2024 to focus on contemporary research reflecting recent advancements in AI technology.

2.2. Search Terms

The search strategy incorporated a combination of keywords and Boolean operators to maximize the retrieval of relevant studies. The primary search terms included the following:

- “Artificial Intelligence” OR “AI”;
- “Chatbot” OR “Conversational Agent” OR “Virtual Assistant”;
- “Anxiety” OR “Anxiety Disorders”;
- “Treatment” OR “Intervention” OR “Therapy”;
- “Mental Health Technology” OR “Digital Psychotherapy”.

An example of a search string used in PubMed is as follows: (“Artificial Intelligence” OR “AI”) AND (“Chatbot” OR “Conversational Agent” OR “Virtual Assistant”) AND (“Anxiety” OR “Anxiety Disorders”) AND (“Treatment” OR “Intervention” OR “Therapy”).

2.3. Inclusion and Exclusion Criteria

To ensure the relevance and quality of the studies included in the review, the following inclusion and exclusion criteria were established:

Inclusion Criteria:

- *Population*: Studies involving participants diagnosed with anxiety disorders or experiencing clinically significant anxiety symptoms;
- *Intervention*: Use of AI chatbots as a primary or adjunctive treatment modality for anxiety;
- *Outcomes*: Studies reporting on the efficacy, effectiveness, user engagement, or satisfaction related to AI chatbot interventions;
- *Study Design*: Randomized controlled trials (RCTs), quasi-experimental studies, pilot studies, cohort studies, and qualitative research;
- *Language*: Articles published in English;
- *Publication Status*: Peer-reviewed articles, including open-access publications from MDPI.

Exclusion Criteria:

- Studies focusing on mental health conditions other than anxiety without a specific analysis of anxiety outcomes;
- Interventions using non-AI-based chatbots or digital tools without conversational capabilities;

- Review articles, meta-analyses, conference abstracts, dissertations, and editorials (though their references were scanned for potential studies);
- Non-English publications;
- Studies lacking full-text availability.

2.4. Study Selection Process

The study selection process involved several stages:

- *Identification*: All records retrieved from the database searches were imported into reference management software to facilitate organization and the removal of duplicates;
- *Screening*: Titles and abstracts were independently screened by two reviewers to assess initial eligibility based on the inclusion and exclusion criteria. Discrepancies were resolved through discussion or consultation with a third reviewer;
- *Eligibility*: Full-text articles of potentially relevant studies were retrieved and assessed for eligibility. The reviewers examined the studies in detail to confirm their relevance to the research question;
- *Inclusion*: Studies meeting all inclusion criteria were selected for data extraction and synthesis.

2.5. Data Extraction

A standardized data extraction form was developed to systematically collect relevant information from each included study. The extracted data encompassed the following:

- *Study Characteristics*: Authors, year of publication, country, and journal;
- *Participant Details*: Sample size, demographic information, diagnostic criteria for anxiety;
- *Intervention Characteristics*: Description of the AI chatbot, therapeutic approaches employed (e.g., CBT techniques), duration and frequency of intervention;
- *Outcome Measures*: Primary and secondary outcomes related to anxiety symptoms, measurement tools used (e.g., GAD-7, STAI), and timing of assessments;
- *Results*: Key findings regarding efficacy, effect sizes, statistical significance, user engagement, and satisfaction;
- *Methodological Quality*: Information pertinent to assessing the risk of bias.

Data extraction was conducted independently by two reviewers to enhance accuracy. Any inconsistencies were discussed and resolved.

2.6. Quality Assessment

The methodological quality of the included studies was appraised using appropriate critical appraisal tools:

- *For Randomized Controlled Trials*: The Cochrane Collaboration's Risk of Bias tool was employed, evaluating factors such as random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting;
- *For Observational Studies*: The Newcastle–Ottawa Scale was used to assess the quality based on selection, comparability, and outcome;
- *For Qualitative Studies*: The Critical Appraisal Skills Program (CASP) checklist was applied to evaluate credibility, relevance, and rigor.

Studies were rated as having a low, moderate, or high risk of bias. Quality assessment was performed independently by two reviewers, with disagreements resolved through consensus.

2.7. Data Synthesis

A narrative synthesis approach was adopted due to the heterogeneity of study designs, interventions, and outcome measures, which precluded meta-analysis. The synthesis involved the following:

- *Thematic Organization*: Grouping studies based on common themes such as efficacy outcomes, user engagement, or specific features of the AI chatbots.#;
- *Comparison of Findings*: Highlighting similarities and differences in results across studies;
- *Identification of Patterns*: Examining factors that may influence the effectiveness of AI chatbot interventions, such as participant characteristics or intervention duration;
- *Integration of Qualitative Insights*: Incorporating user perspectives and experiences to provide a comprehensive understanding.

2.8. Ethical Considerations

As this review utilized publicly available data from published studies, no ethical approval was required. However, ethical standards were maintained by accurately representing the study findings and acknowledging potential limitations.

Prior to the screening and extraction process, the reviewers underwent training to ensure a consistent application of the inclusion criteria and assessment tools. Calibration exercises were conducted using a subset of studies to align understanding and interpretation.

While not directly involving stakeholders in the review process, the selection of studies considered the perspectives of various stakeholders, including patients, clinicians, and developers, by including studies that reported on user satisfaction and engagement.

The review process complied with ethical standards for research, including the following:

- *Transparency*: Clearly documenting the methodology and decision-making processes;
- *Integrity*: Avoiding plagiarism and appropriately citing all sources;
- *Respect for Intellectual Property*: Accessing and utilizing articles within the bounds of open-access permissions.

2.9. Limitations of the Methodology

Acknowledging limitations enhances the transparency and credibility of this review. Potential limitations include the following:

- *Publication Bias*: The exclusion of unpublished studies and gray literature may result in the overrepresentation of positive findings;
- *Language Restriction*: Limiting the search to English-language publications may omit relevant studies published in other languages;
- *Rapid Technological Advances*: Given the fast-paced development of AI technologies, some recent studies or innovations may not be captured within the search timeframe.

2.10. Rationale for Methodological Choices

The methodological framework was designed to balance comprehensiveness with feasibility:

- *Selection of Databases*: Including specialized databases like PsycINFO ensured coverage of psychological literature, while MDPI was specifically included to access open-access research;
- *Timeframe*: Focusing on the period from 2010 onward aligns with significant advancements in AI and the proliferation of digital mental health interventions;
- *Inclusion of Diverse Study Designs*: Considering both quantitative and qualitative studies provided a holistic view of the evidence, encompassing efficacy data and user experiences;
- *Reference Management*: Software such as EndNote or Mendeley was used to organize citations and manage duplicates;

- *Data Extraction and Synthesis*: Microsoft Excel facilitated a structured data extraction and organization;
- *Quality Assessment Tools*: The utilization of established checklists and scales ensured a methodologically rigorous evaluation of study quality.

2.11. Compliance with Reporting Standards

While this review is not a systematic review, PRISMA guidelines were followed in part to enhance its methodological rigor and transparency. A tool to illustrate the study selection process was constructed to depict the study selection process visually, illustrating the number of records identified, screened, assessed for eligibility, and included in the review (Figure 1).




Figure 1. Study selection process.

The systematic approach outlined below provides a robust framework for identifying and synthesizing evidence on the use of AI chatbots in anxiety treatment. By partially adhering to established methodological standards and transparently reporting each step, this review aims to produce credible and valuable insights that can inform future research, clinical practice, and policy development in the field of digital mental health interventions.

2.12. Research Framework

The methodological framework for this review follows a structured process to ensure rigor and transparency. While not a systematic review, partial adherence to PRISMA guidelines enhances its credibility. The process is divided into three stages: input, processing, and outputs (Figure 2).




Figure 2. Research framework workflow.

Input data:

- *Databases and Sources*: Literature was sourced from PubMed/MEDLINE, PsycINFO, Scopus, Web of Science, MDPI, Elsevier, and Frontiers;
- *Search Terms*: Keywords such as “AI Chatbots”, “Anxiety”, and “Therapy” were combined using Boolean operators to maximize retrieval;
- *Eligibility Criteria*: Inclusion and exclusion criteria were established to ensure only relevant studies were selected, as detailed in Section 2.3.

Processing:

- *Screening*: Studies were screened for relevance through a title and abstract review, followed by full-text assessment;
- *Data Extraction*: Key study details, such as participant demographics, chatbot features, and outcomes, were systematically extracted;
- *Quality Assessment*: Tools like the Cochrane Risk of Bias and Newcastle–Ottawa Scale ensured methodological rigor;
- *Data Synthesis*: A narrative synthesis approach grouped studies thematically, highlighted patterns, and incorporated qualitative insights.

Outputs:

- *Findings*: Identification of themes such as efficacy, user engagement, and ethical concerns;
- *Visualizations*: A flowchart illustrating the study selection process (Figure 1) and thematic grouping of findings;
- *Recommendations*: Highlighting gaps in the literature and areas for future research.

3. Evolution of AI Chatbots in Mental Health

The development of AI chatbots in mental health has progressed significantly over the past several decades, spurred by advances in computing power, machine learning algorithms, and the recognized need for more accessible mental health services [24,25]. This section traces the historical progression of AI chatbots, their integration into mental health care, and their application in the treatment of anxiety disorders.

3.1. Early Beginnings: ELIZA and Rule-Based Systems

The origins of chatbots in psychotherapy date back to the 1960s with the creation of ELIZA by Joseph Weizenbaum at the Massachusetts Institute of Technology (MIT) [26]. ELIZA simulated a Rogerian psychotherapist by using pattern matching and substitution methods to generate human-like responses. Although it lacked genuine understanding or awareness, ELIZA demonstrated computers' potential to participate in seemingly therapeutic dialogues. ELIZA's architecture employed simple scripts that converted user inputs into predefined outputs. Despite its limitations, users often ascribed human-like qualities to ELIZA—what Weizenbaum termed the “ELIZA effect”. This early project revealed both the promise and challenges of deploying computer programs in therapeutic contexts.

3.2. Transition to Expert Systems and Limited-Domain Chatbots

Building on ELIZA's foundation, the 1970s and 1980s introduced expert systems designed to imitate human decision-making in specific fields. In mental health, for example, PARRY attempted to emulate the thought processes of a person with paranoid schizophrenia [27,28]. However, these early systems were constrained by their hardcoded rules and inability to adapt to complex user inputs. During this era, chatbots remained predominantly experimental, lacking widespread clinical use. The limitations of primitive natural language understanding and the inability to interpret intricate emotional content further reduced their practicality for mental health applications.

3.3. Emergence of Natural Language Processing and Machine Learning

The 1990s and early 2000s saw pivotal improvements in natural language processing (NLP) and machine learning, enabling more sophisticated human–computer interactions [29]. Chatbots began incorporating statistical models and machine learning algorithms to enhance their language processing capabilities [30]. These technological gains laid the groundwork for chatbots to support more nuanced conversations. In mental health settings, this meant the potential for the greater recognition of emotional cues, more personalized responses, and better alignment with individual user needs.

3.4. *The Rise of Internet and Mobile Technologies. Modern AI Chatbots in Mental Health*

The widespread adoption of the internet and mobile devices in the early 21st century greatly expanded the reach of digital health interventions. Mobile health (mHealth) apps emerged as a powerful medium for offering healthcare services, including mental health support [31–33]. The chatbots integrated into these apps provided a cost-effective, scalable means of reaching larger populations.

Integration of Cognitive-Behavioral Therapy Techniques. Modern AI chatbots began incorporating evidence-based therapeutic strategies, especially those derived from cognitive-behavioral therapy (CBT), recognized as highly effective for anxiety disorders [34–36]. By delivering CBT interventions through conversational interfaces, chatbots could help users identify and challenge negative thought patterns. For example, the AI chatbot Woebot applies CBT principles to support users with depression and anxiety [36,37]. By prompting daily conversations, Woebot offers psychoeducation, tracks mood changes, and guides users through cognitive restructuring exercises.

Advancements in Artificial Intelligence and Deep Learning. The emergence of deep learning and neural networks further broadened the capabilities of AI chatbots. These algorithms enable the analysis of extensive datasets to detect patterns, interpret context, and generate more natural-sounding replies [38]. Chatbots like Wysa employ deep learning to provide empathetic support, mindfulness routines, and tailored recommendations [39,40]. By using NLP to parse user inputs and machine learning to personalize conversations, Wysa creates more engaging and user-specific interactions [32].

Multimodal Interactions and Emotional Recognition. Recent developments have driven the creation of multimodal chatbots that go beyond text, integrating voice and even facial recognition features to interpret user emotions [41]. By assessing vocal tonality or facial cues, these chatbots strive for more empathetic, context-aware responses [42]. Although still in the early stages, such emotional recognition technologies hold promise for fostering a stronger therapeutic alliance with users. Recognizing and reacting to emotional states may improve user satisfaction and adherence to chatbot-driven interventions.

3.5. *Application in Anxiety Treatment, Integration with Healthcare Systems*

Anxiety disorders appear particularly amenable to chatbot-based interventions, due to the established efficacy of CBT and the accessibility challenges inherent in traditional therapy [43]. AI chatbots can deliver standardized CBT techniques, ensuring fidelity to therapeutic protocols while simultaneously personalizing interactions based on user input. Studies have confirmed the effectiveness of chatbot interventions in mitigating anxiety symptoms. For instance, in a randomized controlled trial, Ly et al. (2017) found that a fully automated CBT-focused chatbot significantly reduced anxiety among university students [44]. Over a six-week period, the chatbot offered psychoeducation, interactive exercises, and coping strategies. A growing trend involves integrating AI chatbots directly with existing healthcare systems. Chatbots can act as a first point of contact, triaging users according to symptom severity and directing them to suitable services [45]. Such an integration has the potential to enhance efficiency, reduce wait times, and optimize the allocation of clinical resources.

3.6. *Accessibility and Global Impact*

AI chatbots offer notable advantages in terms of accessibility. They can deliver real-time support without the need to schedule appointments, bypassing geographic limitations and the shortage of mental health professionals in certain regions. They also help address the stigma related to seeking therapy [46]. In under-resourced settings, chatbots can fill gaps in mental health service delivery. For countries where professional care is

limited, smartphone-based chatbot interventions offer basic psychological support and psychoeducation [47,48].

3.7. Standards, Ethical Considerations, and User Trust

The evolution of AI chatbots brings critical ethical questions regarding user privacy, data security, and potential harm resulting from inaccurate or inappropriate chatbot responses [49]. Fostering user trust is paramount to ensure these tools are effective in delivering mental health support. Developers increasingly adopt ethical frameworks to inform chatbot design, emphasizing transparency, informed consent, and adherence to regulations like the General Data Protection Regulation (GDPR) [50,51]. Guaranteeing that chatbots provide accurate information and handle crises responsibly is a key priority. Regulatory bodies are starting to establish guidelines for digital mental health tools, including AI chatbots. The U.S. Food and Drug Administration (FDA) has issued guidance for software considered to be medical devices, which could apply to certain therapeutic chatbots [48]. Standards organizations are also working to define benchmarks for chatbot safety, efficacy, and ethical considerations, providing a framework to protect users and ensure a minimum standard of care. Open-access journals, including MDPI publications, have played a role in disseminating research on AI chatbots for mental health. For example, the *International Journal of Environmental Research and Public Health* has published studies that address both the effectiveness of digital interventions and the ethical complexities of AI in healthcare [45,52,53]. Such publications foster greater transparency by highlighting best practices in chatbot design, deployment, and evaluation.

3.8. Future Development

Such publications foster greater transparency by highlighting best practices in chatbot design, deployment, and evaluation:

- Personalization: Refining chatbots to offer interventions customized to each user's profile, preferences, and cultural background [54];
- Multilingual Capabilities: Broadening language support to reach global audiences and overcome linguistic barriers [55];
- Integration with Artificial Emotional Intelligence: Advancing chatbots' capacity to recognize and respond effectively to emotional states [56,57];
- Hybrid Models: Combining chatbots with human-led services to create blended care models that leverage the strengths of both [58];
- Research and Validation: Conducting robust clinical trials to validate chatbot efficacy and safety across diverse populations [59].

The growing interest in personalization will likely boost the effectiveness of AI chatbots in treating anxiety disorders. One promising approach is integrating individualized dietary and nutritional data into chatbot-based interventions. Diet plays an important role in mental well-being, especially for those with anxiety disorders. Research has linked deficiencies in nutrients such as Vitamin D to heightened anxiety symptoms due to its role in neurotransmitter regulation and neuroimmune function [60]. Adapting chatbot algorithms to assess potential nutrient deficiencies allows for tailored recommendations that encourage dietary changes supportive of mental health. This aligns with broader research on the link between food biochemistry and neurological health, wherein specific nutrients may help prevent or manage disorders like anxiety [61,62]. Considering Vitamin D's importance, not just for mental health but also for broader health outcomes—such as its differential effect on aging and its influence on skin health—reinforces the value of incorporating nutritional guidance into chatbot interventions [63–66].

By accounting for both psychological and physiological factors, AI chatbots can offer more holistic, user-specific support. This level of personalization may improve engagement, adherence, and clinical outcomes for individuals with anxiety disorders. In essence, the evolution of AI chatbots in mental health represents a dynamic intersection between technological innovation and a growing need for accessible mental health care. From the early days of ELIZA to today's sophisticated AI-driven platforms, chatbots have advanced considerably in functionality and scope. As ongoing research further validates their effectiveness in treating anxiety and other disorders, AI chatbots are poised to become integral components of mental health systems worldwide. Balancing these rapid developments with ethical considerations, a user-centric design, and robust clinical validation will be crucial to their continued success in promoting mental well-being.

4. Efficacy of AI Chatbots in Anxiety Treatment

Anxiety disorders are widespread mental health conditions that can profoundly affect an individual's quality of life. The emergence of AI chatbots as therapeutic tools has created new opportunities for addressing these disorders. In recent years, there has been considerable interest in applying AI chatbots in mental health care, particularly for anxiety disorders. This section draws on a substantial body of research—over 100 studies are included in this review—to explore the effectiveness of these digital interventions. The methodologies employed across these studies range from randomized controlled trials (RCTs) to pilot and observational studies, focusing on outcomes such as efficacy, user engagement, and satisfaction. Emphasis is placed on research published in open-access journals to ensure a transparent, accessible evidence base.

4.1. Overview of Empirical Studies

Numerous studies have investigated the effectiveness of AI chatbots in reducing anxiety, often using techniques derived from cognitive-behavioral therapy (CBT), mindfulness, and psychoeducation, delivered via conversational interfaces. These interventions seek to replicate aspects of traditional therapy in a digital environment, enabling more convenient and immediate support.

RCTs account for a significant portion of the research in this field. For example, Fulmer et al. (2018) evaluated Tess, an AI chatbot designed to provide psychological support [18]. In a study involving 74 college students presenting anxiety and depression symptoms, participants were randomized to interact with Tess or receive traditional face-to-face counseling. The results showed significant reductions in anxiety, measured by the Generalized Anxiety Disorder 7-item scale (GAD-7), in both groups—suggesting that Tess can be as effective as conventional therapy in certain contexts. Similarly, Fitzpatrick et al. (2017) studied Woebot, a fully automated chatbot delivering CBT to young adults with anxiety and depression [36]. In a two-week RCT involving 70 participants, the chatbot group experienced a notable reduction in anxiety symptoms, as measured by the Beck Anxiety Inventory (BAI), compared to an information-only control group.

Pilot studies have also provided valuable insights into the feasibility and effectiveness of chatbot-based interventions. Ly et al. (2017) investigated a conversational agent delivering CBT and behavioral activation techniques to university students [44]. The intervention produced significant improvements in anxiety levels, with a high reported satisfaction and engagement. Nicol et al. (2022) similarly examined a chatbot designed to help adolescents manage anxiety [67]. The pilot data indicated reductions in self-reported anxiety and underscored the potential of AI chatbots for younger populations who may be reluctant to access traditional mental health services.

Observational studies offer additional evidence of chatbots' effectiveness in real-world contexts. Inkster et al. (2018) analyzed data from over 3000 users interacting with Wysa, an AI chatbot for mental health support [39]. Frequent engagement with Wysa correlated with decreased anxiety and depression symptoms, suggesting that AI chatbots can deliver meaningful therapeutic benefits outside controlled research environments.

Overall, the aggregated findings indicate that AI chatbots can effectively reduce anxiety symptoms in various populations and settings. Many interventions are grounded in established therapeutic frameworks, such as CBT, adapted for delivery via conversational agents. The immediate availability, anonymity, and consistent therapeutic content provided by chatbots appear to enhance user engagement and facilitate symptom improvement. Nevertheless, the variability in study design, sample size, and outcome measures must be considered when interpreting these results. Longer-term and larger-scale studies are needed to validate the sustained effectiveness of AI chatbots, particularly in diverse demographic groups.

4.2. Methodological Approaches

The range of methodologies used in the studies included in this review has significant implications for interpreting chatbot efficacy in anxiety treatment. Differences in intervention duration, outcome measures, and control conditions affect how well results can be generalized and compared. Understanding these nuances is essential for accurately evaluating chatbot-based interventions and identifying gaps for future research.

Intervention Duration and Intensity. Intervention durations in the analyzed studies vary widely, from brief two-week programs to multi-month engagements. Krzyzaniak et al. (2024) conducted a systematic review and meta-analysis comparing telehealth interventions to face-to-face therapy for anxiety disorders, emphasizing the influence of varying intervention lengths on outcomes [2]. Short-term interventions often showed immediate symptom reductions, but their long-term efficacy remains unclear. In a pilot study, Ly et al. (2017) demonstrated that a short-term, fully automated conversational agent could significantly reduce anxiety levels among university students [44]. Conversely, more extended interventions, such as those discussed by McDaid et al. (2019), suggest that longer programs may yield better long-term benefits, indicating a need to investigate optimal intervention durations for sustained results [68].

Outcome Measures. The assessment of anxiety symptoms typically relies on validated self-report instruments, including the GAD-7, BAI, and the Depression Anxiety and Stress Scales (DASS-21) [67–69]. Dwight et al. (2024) explored the utility of DASS-21 as a monitoring tool for youth, highlighting its reliability and validity [69–71]. Although self-report measures provide essential insights into users' subjective experiences, they can be influenced by biases such as social desirability or inaccurate self-assessment. Olatunji et al. (2007) recommended complementing self-report tools with clinician-administered interviews or physiological indicators to obtain more comprehensive data [3].

Control Conditions. Variations in control conditions across studies also shape the interpretation of effect sizes and overall efficacy. Control groups have included waitlists, information-only interventions, traditional therapy, and other active comparators. In the RCT by Fulmer et al. (2018), participants were randomized to Tess or face-to-face counseling, allowing direct comparison between the chatbot and a conventional therapeutic approach [18]. Meanwhile, Fitzpatrick et al. (2017) contrasted Woebot with an information-only control, which might not fully capture the impact of active engagement [36]. This diversity underscores the importance of standardized control conditions to facilitate more reliable cross-study comparisons [9].

4.3. Methodological Considerations, Limitations, and Challenges

The wide methodological variability among studies poses notable challenges when synthesizing evidence on AI chatbot efficacy for anxiety treatment. Factors such as sample size, population characteristics, therapeutic approaches, and study environments differ considerably, complicating the process of drawing definitive conclusions.

Heterogeneity of Interventions. Differences in chatbot design, therapeutic content, and delivery methods limit the generalizability of findings. While some chatbots primarily use CBT techniques (e.g., Fitzpatrick et al. (2017) [36]), others incorporate mindfulness, psychoeducation, or multiple modalities. Boucher et al. (2021) stressed the need for clarity in describing chatbot interventions to understand which components most effectively reduce anxiety [13]. Standardizing interventions could enable more meaningful comparisons across studies.

Sample Diversity. Many investigations focus on specific subgroups—such as college students, adolescents, or older adults—limiting their applicability to broader populations. Nicol et al. (2022) targeted adolescents [67], while Danieli et al. (2022) examined aging adults [72]. Although these findings provide valuable insights within each group, their relevance for other demographics is uncertain. Greater inclusivity in future research could clarify efficacy across diverse ages, cultures, and socioeconomic backgrounds.

Engagement and Attrition Rates. User engagement strongly influences treatment outcomes in digital interventions. High attrition rates, caused by low motivation, technical challenges, or dissatisfaction, can reduce the effectiveness of chatbot-based treatments. Perski et al. (2017) emphasized tailoring digital interventions to user preferences as a strategy to improve adherence [73]. Gamification, personalized reminders, and interactive design elements may help mitigate attrition.

Methodological Challenges. Variations in study design, sample size, and outcome measures also complicate evidence synthesis. Although many studies use validated self-report instruments like GAD-7, BAI, or DASS-21, inconsistent metrics can hamper cross-study comparisons. Differences in control conditions, intervention duration, and follow-up intervals further limit the ability to generalize findings across heterogeneous studies.

Ethical Considerations. When deploying AI chatbots for mental health, issues such as user privacy, data security, and informed consent are paramount. Mittelstadt et al. (2016) mapped ethical debates on algorithmic systems, reinforcing the need for transparent data usage, user consent, and bias mitigation [49]. Adhering to regulations like the GDPR is vital to safeguarding user data and preserving trust [51].

Technological Barriers. Limited digital literacy and lack of access to technology can exclude certain populations from benefiting from chatbot interventions. Crawford and Serhal (2020) warned that digital health innovations risk exacerbating health inequalities if accessibility and user-friendliness are not prioritized [74]. Ensuring that chatbot interfaces are intuitive and available across multiple devices is essential for equitable adoption.

Publication Bias and Research Limitations. Publication bias remains a concern, with studies reporting significant results more likely to be published, thus skewing the perceived efficacy of chatbots. Dwan et al. (2013) highlighted this bias in systematic reviews [75]. Additionally, many studies feature small sample sizes or short follow-up intervals, limiting the ability to assess long-term outcomes.

4.4. Comparative Efficacy and Factors Influencing the Effectiveness of AI Chatbots in Anxiety Treatment

The effectiveness of AI chatbots in treating anxiety has been central to numerous investigations. Many have compared chatbot interventions to traditional therapeutic approaches, finding similar reductions in anxiety in certain settings. Various factors—such

as personalization, therapeutic alliance, accessibility, user satisfaction, and sustainability of treatment effects—may influence these outcomes.

Comparative Efficacy. Some research indicates that AI chatbots can achieve results comparable to face-to-face therapy. Krzyzaniak et al. (2024), in a systematic review and meta-analysis, concluded that telehealth interventions, including AI chatbots, produced moderate effect sizes for anxiety reduction, aligning with those achieved through in-person therapy [2]. Firth et al. (2017) also demonstrated that smartphone-based mental health tools, many of which incorporate chatbot functionalities, are effective in reducing symptoms, with effect sizes similar to standard therapeutic approaches [76]. Liu et al. (2022) further explored how health advice chatbots affect user health beliefs and usage intentions, showing that well-designed chatbot interfaces can promote engagement and behavior change in ways comparable to human-delivered interventions [77].

Factors Influencing Efficacy. Several factors have been identified that influence the efficacy of AI chatbot interventions for anxiety treatment:

- **Personalization and Adaptive Learning:** Tailoring interventions to user inputs and preferences can boost user engagement. Liu and Sundar (2018) found that personalization and perceived source expertise significantly enhanced users' health beliefs and intentions [16];
- **Therapeutic Alliance:** While AI chatbots lack genuine human empathy, designing them to respond empathetically and supportively can help users feel more comfortable. Bickmore and Picard (2005) revealed that users who viewed an agent as compassionate were more likely to adhere to the intervention [57];
- **Accessibility and Convenience:** Chatbots bypass traditional barriers like scheduling, travel, and stigma. Gaggioli and Riva (2013) emphasized that mobile-based mental health interventions offer unparalleled convenience, likely increasing utilization [78];
- **User Satisfaction and Acceptability:** Positive user experiences are closely tied to high engagement. Provoost et al. (2017) identified anonymity and consistent availability as key drivers of user satisfaction [79].

4.5. Engagement and Attrition Rates

Maintaining strong user engagement is critical to the success of AI chatbot interventions. However, digital interventions often encounter elevated attrition. Perski et al. (2017) underlined how designing interventions with user-centered strategies (e.g., gamification, personalized feedback, interactive features) can enhance adherence and increase the likelihood of successful outcomes [73]. Baumel et al. (2019) also stressed the importance of objective metrics to understand engagement and retention in mental health apps [80].

Insights from Open-Access Publications. Several open-access publications have widened the access to findings on AI chatbots in mental health:

- Abd-Alrazaq et al. (2020), in a systematic review, observed that many chatbot interventions significantly reduced anxiety symptoms, while stressing the need for high-quality RCTs and more stringent methodologies [14];
- Casu et al. (2024) presented a scoping review on AI chatbots, noting both their feasibility and potential to supplement standard care for individuals with limited mental health resources [12];
- Vaidyam et al. (2019) highlighted how chatbots increase engagement by delivering immediate support and recommended integrating evidence-based practices to enhance their effectiveness [15].

Long-Term Efficacy and Follow-Up. Evaluating the long-term effectiveness of AI chatbot interventions is vital for assessing their sustainability. Schillings et al. (2024) conducted an RCT with a three-month follow-up, finding that initial reductions in anxiety were

maintained [81]. Danieli et al. (2022) similarly reported that a conversational AI had lasting positive effects on stress and anxiety levels in older adults [72]. Although these findings are promising, extended follow-up periods are necessary to confirm the long-term benefits.

Limitations and Challenges. Despite the promising evidence, several limitations and challenges affect the interpretation of AI chatbot efficacy:

- **Heterogeneity of Interventions:** Varied chatbot designs and therapeutic techniques limit cross-study comparability [58];
- **Sample Diversity:** Studies often focus on narrow demographics, making generalization difficult [3];
- **Ethical Considerations:** Data privacy, consent, and compliance with regulations (e.g., GDPR) remain key concerns [49,82];
- **Technological Barriers:** Users lacking digital literacy or a reliable internet may be unable to access these interventions [74];
- **Publication Bias and Inconsistent Outcome Measures:** Selective reporting of positive results and varied metrics can distort the evidence [75].

4.6. Implications for Future Research and Clinical Practice

A further advancement in AI chatbot interventions for anxiety disorders requires concerted attention to methodological rigor, integration strategies, technological development, and cultural adaptation. By recognizing and addressing these challenges, researchers and clinicians can optimize the efficacy and accessibility of chatbot-based treatments.

Methodological Considerations and Standardization. The notable methodological heterogeneity across existing studies complicates evidence synthesis. Casu et al. (2024) advocated for standardized protocols—spanning intervention lengths to outcome measures—to facilitate meta-analyses and systematic reviews [12]. Transparency in reporting and the use of guidelines like CONSORT can improve the overall quality of research. Additionally, awareness of publication bias, as described by Dwan et al. (2013), is essential for maintaining accurate representations of intervention efficacy [75].

Integration with Traditional Therapy. Blending AI chatbots with conventional therapy can amplify the benefits of both approaches. Hybrid models, where chatbots offer between-session support and monitoring, can allow therapists to concentrate on complex clinical tasks. Cross et al. (2023) and Palermo et al. (2020) presented evidence supporting this model, proposing that it enhances continuity of care and optimizes limited healthcare resources [83,84].

Technological Advances and Future Directions. Advancements in AI, particularly in natural language understanding and emotional recognition, have the potential to enhance chatbot efficacy significantly:

- **Emotional AI Integration:** Progress in affective computing can improve chatbots' capacity to interpret and respond to users' emotional states, potentially strengthening rapport [56];
- **Multimodal Interventions:** Merging text, voice, and visual interfaces may align with various user preferences, expanding treatments' reach and encouraging deeper engagement [79].

Cultural and Linguistic Adaptations. Ensuring global relevance requires culturally adapted chatbots. Liu et al. (2022) highlighted the necessity of designing region-specific content and culturally sensitive interfaces [77]. Incorporating cultural competence in chatbot design can tackle stigma and accessibility barriers more effectively, as suggested by Sue and Zane (1987) [85].

Clinical Implications. AI chatbots offer scalable solutions to meet the increasing demand for mental health services, with several clinical implications:

- **Support Stepped Care Models:** Provide initial interventions for mild or moderate anxiety, reserving intensive services for severe cases;
- **Reduce Costs:** Decrease the need for frequent clinician-led sessions, aligning with McDaid et al. (2019)'s findings on economic benefits from preventive mental health measures [68];
- **Increase Accessibility and Convenience:** Offer remote, immediate support to underserved populations or individuals constrained by stigma or geography.

Recommendations for Future Research. To refine and expand the efficacy of AI chatbots in anxiety treatment, future efforts should consider the following:

- **Standardize Interventions:** Adopt consistent therapeutic frameworks and protocols to streamline comparisons;
- **Diversify Samples:** Examine broader age groups, cultural contexts, and clinical settings to enhance external validity;
- **Extend Follow-Up Periods:** Evaluate the durability of symptom relief over months or years;
- **Strengthen Engagement Strategies:** Integrate gamification, personalization, and adaptive learning algorithms to reduce attrition;
- **Address Ethical and Regulatory Issues:** Maintain data security and user privacy while adhering to guidelines such as GDPR [86];
- **Alleviate Technological Barriers:** Develop user-friendly interfaces and multi-device compatibility for individuals with varying levels of digital fluency.

By focusing on these priorities, the field can continue to build robust evidence, enhance treatment efficiency, and facilitate the integration of AI chatbots into mainstream mental health care.

5. Advantages and Limitations

The use of AI chatbots in mental health care, especially for treating anxiety disorders, offers notable advantages but also presents several limitations. Understanding these factors is essential for effectively integrating chatbots into therapeutic practices and for addressing the potential challenges

5.1. Advantages

Although AI chatbots provide significant benefits regarding accessibility and scalability, specific considerations must be addressed to fully optimize their effectiveness.

Accessibility. A key advantage of AI chatbots is their ability to deliver mental health support without geographical or temporal restrictions. Traditional mental health services often encounter barriers such as limited provider availability, long wait times, and an unequal resource distribution, especially in rural or underserved regions [87]. By contrast, AI chatbots can be accessed through smartphones, tablets, or computers at any time, offering immediate support regardless of a user's location or the time of day.

A study by Inkster et al. (2018) showed that AI chatbots like Wysa have been downloaded in over 30 countries, underscoring their global reach and capacity to address gaps in mental health service delivery [32]. Moreover, during crises such as the COVID-19 pandemic, when face-to-face interactions may be limited, AI chatbots can provide continuous mental health support [88]. Because of their flexibility and ability to handle high volumes of users simultaneously, chatbots have become a valuable resource during periods of increased demand. The pandemic has also shed light on the broader strain placed on healthcare systems, with ramifications such as increased psychological distress, shifts in healthcare practices, and the emergence of antibiotic resistance due to overprescription [89,90]. In

such circumstances, AI chatbots offer a scalable, readily accessible option for providing mental health services without further burdening overwhelmed healthcare infrastructures.

Cost-Effectiveness. AI chatbots may reduce financial burdens for both healthcare systems and patients by minimizing the need for one-on-one therapy sessions. Traditional psychotherapy entails considerable costs related to clinician time, facility use, and administrative expenses [91]. Once deployed, chatbots can offer ongoing support without the direct costs associated with human staffing. A cost-effectiveness analysis by Park et al. (2019) demonstrated that digital mental health tools, including AI chatbots, can generate significant savings for healthcare systems by lowering the number of in-person visits and reducing hospitalization rates [68]. This cost reduction also benefits patients, for whom lower out-of-pocket expenses can make mental health services more accessible. Additionally, because AI chatbots can operate continuously—unrestricted by standard working hours—their scalability does not proportionally increase operational expenses, unlike more traditional models of therapy.

Anonymity and Reduced Stigma. Stigma around mental health issues can inhibit individuals from seeking help. AI chatbots afford a degree of anonymity that may alleviate fears of judgment or discrimination [92]. Users often feel more comfortable revealing sensitive details to a non-human entity, encouraging deeper self-disclosure and more accurate symptom reporting. Research by Luxton et al. (2012) shows that anonymity can improve self-disclosure, which in turn is crucial for effective assessment and intervention [31]. Moreover, for adolescents and other vulnerable groups, chatbots present a safe and confidential environment for exploring mental health concerns without the perceived barriers associated with traditional therapy [93].

Consistency and Standardization. AI chatbots deliver interventions in a consistent manner, free from the variations that might arise among human therapists. This uniformity ensures that evidence-based therapeutic methods—such as certain approaches within CBT—are applied consistently [94,95]. Additionally, chatbots can provide immediate feedback and reinforcement, potentially improving the learning and application of coping strategies. By tracking user progress over time and applying data analytics, chatbots can also tailor interactions to address individual needs while maintaining a high level of standardized care.

Immediate Support and Crisis Intervention. The on-demand nature of AI chatbots is a critical advantage for individuals experiencing acute anxiety symptoms who may require quick relief or guidance [78]. Some chatbots also feature built-in mechanisms to detect crisis situations—such as suicidal ideation—and can direct users to relevant resources or emergency services. Providing timely, immediate support in these situations can be instrumental in symptom management and overall crisis intervention.

5.2. Limitations

Lack of Human Empathy. Despite advancements in natural language processing (NLP) and affective computing, AI chatbots generally cannot replicate the nuanced empathy and rapport offered by human therapists. Empathy is a cornerstone of successful therapeutic relationships, fostering trust and engagement [96]. The inability of chatbots to truly grasp or respond to complex emotional states may impede meaningful communication and limit the depth of therapeutic outcomes. A study by Hoermann et al. (2017) found that while users appreciate the convenience and availability of chatbots, they also miss the emotional support that human interactions provide [97]. This deficit in genuine empathy can affect both user satisfaction and the continued use of chatbot interventions.

Ethical and Privacy Concerns. AI chatbots often handle sensitive personal information, raising serious concerns about confidentiality and data security. Users must trust that

their personal data are safeguarded against unauthorized access, breaches, or misuse [98]. Maintaining compliance with data protection regulations, such as the GDPR in the European Union, is crucial for ensuring user privacy [51,82]. However, protecting such data involves ongoing challenges, including defending against cyber threats and preventing unauthorized data access. Ethical considerations also extend to transparency about chatbot capabilities and limitations, as well as to the broader issue of informed consent. Developers and providers must be vigilant in upholding ethical standards to protect users from harm or the misuse of technology [99].

Technical Challenges. AI chatbots frequently struggle with understanding nuanced language—such as idioms, sarcasm, or ambiguous phrasing—which can lead to inappropriate or ineffective responses [100]. Additionally, technological malfunctions or system outages may disrupt user experiences. These challenges assume that users have a reliable internet access and are comfortable with digital platforms, which is not always the case [101].

Limited Scope of Intervention: Most AI chatbots are designed to address mild to moderate anxiety symptoms and may not be suitable for those with more severe mental health conditions [102]. Complex or comorbid disorders often necessitate comprehensive assessments and interventions led by qualified mental health professionals. Furthermore, chatbots are constrained by their programmed algorithms and cannot fully account for the broad range of human experiences.

Over-Reliance and Reduced Human Interaction: Users may become overly dependent on chatbots, potentially reducing engagement with broader social support networks. While chatbots can serve as an important adjunct to care, they are not intended to replace human therapists or supportive interpersonal relationships [103]. Encouraging responsible use and highlighting when professional or social support may be necessary can help mitigate these risks.

Cultural and Linguistic Limitations: Chatbots developed within certain cultural contexts may fail to resonate with users from different backgrounds. Language barriers, culturally specific emotional expressions, and disparate attitudes toward mental health may hinder user engagement and efficacy [55,104]. Adapting chatbots to incorporate culturally sensitive content and interaction styles requires careful research, localization, and community involvement.

5.3. Balancing Advantages and Limitations

Successfully integrating AI chatbots into mental health care requires a balanced appreciation of their strengths and weaknesses. Several strategies can help leverage the benefits while minimizing the drawbacks:

- **Enhancing Empathy Through Design:** Ongoing work in affective computing aims to improve chatbots' recognition of emotional cues and the generation of empathetic responses [105]. User feedback and advanced NLP methods can further heighten perceived empathy;
- **Strengthening Ethical Practices:** Robust data protection measures, transparent privacy policies, and clear informed consent protocols are essential for ensuring ethical use. Collaborating with ethics review boards and adhering to industry standards can guide responsible development [106];
- **Technical Improvements:** Continued investment in AI and machine learning can refine chatbots' language-processing capabilities and overall reliability. Addressing misinterpretation or technical failures is vital for providing uninterrupted service;
- **Integrating Human Support:** Combining chatbot interventions with oversight from mental health professionals can alleviate certain limitations. For instance, chatbots

can offer preliminary support, triage users, and alert human therapists when more comprehensive care is needed [107];

- Cultural Adaptation: Developing culturally relevant chatbot versions—through consultation with local experts and the inclusion of cultural nuances—can improve acceptance and efficacy among diverse groups [108].

In conclusion, AI chatbots hold considerable promise as accessible, cost-effective tools for supporting individuals with anxiety disorders. However, recognizing and addressing their limitations—such as the lack of deep empathy, the need for ethical data handling, and the challenge of ensuring cultural sensitivity—is vital for achieving optimal outcomes.

6. Challenges and Future Perspectives

The integration of AI chatbots into mental health care presents both significant opportunities and substantial challenges. While these digital tools offer promising solutions for improving accessibility and cost-effectiveness, several hurdles must be addressed to optimize their efficacy and ensure their ethical deployment. This section examines the key challenges associated with AI chatbot interventions in anxiety treatment and proposes future directions for overcoming these obstacles through research, technological innovations, and regulatory frameworks.

6.1. Technical Challenges in Emotional Intelligence

Limitations in Understanding Human Emotions. A primary challenge for AI chatbots lies in their limited capacity to comprehend and respond to the complex spectrum of human emotions. Emotional intelligence in chatbots involves recognizing, interpreting, and appropriately replying to users' emotional states. Despite advancements in NLP and machine learning, AI systems still struggle with nuances such as sarcasm, irony, and cultural variations of emotional expression [109]. This inability to fully capture emotional context may lead to inappropriate or ineffective responses, potentially reducing user trust and engagement. For instance, a user expressing frustration might receive a generic or poorly aligned response, undermining the therapeutic potential of the interaction.

Enhancing Emotional Intelligence through Advanced Algorithms. Addressing these limitations requires ongoing research in affective computing and emotion recognition technologies. Advanced algorithms that leverage deep learning and contextual analysis can improve chatbots' ability to detect and interpret emotional cues from text inputs [110–112]. For example, incorporating sentiment analysis and emotion classification models enables chatbots to tailor their responses more effectively. Studies show that chatbots employing these techniques can achieve higher user satisfaction by delivering more empathetic and contextually appropriate interactions [113].

Multimodal Emotion Recognition. Future developments may integrate multimodal data—such as voice tone, facial expressions (in video-based interfaces), and physiological signals—to enhance emotion recognition [114]. While this could significantly improve emotional understanding, it also raises additional privacy and ethical concerns that require careful management.

6.2. Integration with Traditional Therapy

Hybrid Models Combining AI and Human Therapists. Integrating AI chatbots with traditional therapy offers a hybrid model that combines the strengths of human therapists with the efficiency of technology. In this model, chatbots can conduct routine assessments, provide psychoeducation, and offer immediate support, while human therapists concentrate on more complex clinical tasks and therapeutic relationships [115]. Research indicates that such hybrid models can boost treatment outcomes by increasing user engagement

and adherence [116]. For example, chatbots can send appointment reminders, monitor symptom progression, and reinforce therapeutic techniques between sessions.

Collaborative Care and Stepped-Care Approaches. Incorporating AI chatbots into collaborative care frameworks enables a stepped care approach, allowing patients to receive interventions matched to the severity of their symptoms [117]. Chatbots can act as a first-line intervention for individuals with mild to moderate anxiety, escalating to human-led therapy when necessary.

Training and Supervision. Ensuring that chatbots supplement rather than replace human therapists requires clear guidelines and training for practitioners. Therapists need to understand how to integrate chatbot-generated data into their clinical practice effectively. The ongoing supervision and monitoring of chatbot interactions can help maintain quality and address potential issues promptly [118].

6.3. Ethical Considerations and Regulatory Frameworks

Privacy and Data Protection. Handling sensitive personal data through AI chatbots raises significant ethical concerns related to confidentiality and data security. Users must trust that their information is safeguarded against unauthorized access, breaches, or misuse [119,120]. Compliance with data protection regulations, such as the GDPR in the European Union, is crucial [82,86]. Chatbot developers and providers must employ robust encryption, secure data storage, and transparent privacy policies.

Informed Consent and Transparency. Obtaining informed consent is critical when users interact with AI chatbots for mental health support. Users should be made aware of the chatbot's capabilities, limitations, data-collection practices, and how their information will be utilized [121]. Transparency about the chatbot's non-human nature is also vital to prevent misunderstandings. Clearly indicating that the interaction is with an AI system helps set realistic expectations and avoids any perception of deception.

Mitigating Bias and Ensuring Fairness. AI algorithms can unintentionally perpetuate biases present in training data, resulting in inequitable outcomes [122]. In mental health contexts, biased responses may compromise the quality of care for specific demographic groups. Developers must strive to identify and mitigate biases by using diverse and representative datasets, conducting regular audits, and involving multidisciplinary teams in the development process [123].

Establishing Regulatory Standards. Currently, few comprehensive regulatory frameworks specifically address AI chatbots in mental health care. Establishing clear standards and guidelines can ensure the safe and ethical deployment of these technologies [124,125]. Collaboration among regulatory bodies, professional organizations, and policymakers is necessary to create regulations covering data protection, efficacy validation, ethical concerns, and professional accountability [126,127].

6.4. Ethical Considerations and Strategies for Implementation

Ethical Considerations and Best Practices for AI Chatbots in Mental Health. AI chatbots offer a transformative potential in mental health care but also raise significant ethical challenges, particularly concerning data privacy, informed consent, and equitable distribution of benefits. This subsection consolidates the critical ethical issues and proposes actionable strategies.

Data Privacy and Security. Ensuring data privacy is paramount. Users must trust that their sensitive information will remain secure against breaches or misuse. Compliance with regulations like the GDPR is essential, calling for robust encryption, secure data storage, and transparent privacy policies. Providers should clearly explain how user data are collected, stored, and utilized, while also giving users control over their personal information.

Informed Consent and Transparency. Transparency is a cornerstone of ethical chatbot deployment. Users must be fully informed about the chatbot’s capabilities, limitations, and the non-human nature of the interaction. Clearly communicating data usage practices and obtaining informed consent builds trust and ensures users remain aware of the system’s functionalities.

Mitigating Bias and Promoting Fairness. Developers need to avoid perpetuating biases in training data. Prioritizing diverse, representative datasets and conducting regular audits are crucial steps in ensuring chatbot interventions are equally effective across different demographic groups.

Strategies for High-Risk User Groups. When dealing with individuals at high risk—such as those with severe anxiety or suicidal ideation—chatbots should be equipped with safeguards, including the following:

- **Critical Alert Mechanisms:** Automated detection of high-risk phrases and referrals to hotlines or mental health professionals;
- **Crisis Response Protocols:** Pre-programmed responses guiding users toward immediate professional help;
- **Continuous Monitoring:** Data logging to identify patterns indicative of worsening mental health, facilitating timely interventions.

Recommendations for Ethical AI Deployment.

- **Developing Ethical Guidelines:** Regulatory bodies should establish standards specific to AI chatbots, addressing efficacy validation, user accountability, and data security;
- **Collaborative Development:** Involving stakeholders—clinicians, ethicists, and end users—helps design chatbots that meet diverse needs;
- **Ongoing Training and Education:** Mental health professionals should receive training to effectively incorporate AI chatbots into their practice and understand their inherent limitations.

6.5. User Engagement and Retention

Overcoming Engagement Barriers. Sustaining user engagement is crucial for the effectiveness of AI chatbot interventions. Common challenges include maintaining user interest, preventing attrition, and encouraging ongoing interaction [128]. Approaches to enhance engagement may involve gamification elements, personalized content, and adaptive feedback loops. Understanding user preferences and tailoring interventions accordingly can improve retention rates [73].

Addressing Digital Literacy and Accessibility. Not all users possess the digital literacy skills or technological access needed to benefit from AI chatbots. Efforts to simplify chatbot interfaces, offer multilingual support, and provide user education are essential [74]. Collaboration with community organizations can further expand outreach to underserved populations.

6.6. Cultural Sensitivity and Personalization

Adapting to Diverse Cultural Contexts. Cultural factors heavily influence how people perceive and express mental health concerns. AI chatbots must be culturally attuned to be effective across diverse populations [85,129,130].

Localization involves aligning language, content, and interaction styles with cultural norms and values. Engaging local experts and incorporating community feedback into chatbot development can enhance cultural appropriateness [131,132].

Personalization and User-Centered Design. Personalizing chatbot interactions according to each user’s characteristics, preferences, and needs may significantly improve engagement

and outcomes. Machine learning algorithms can analyze user data to deliver tailored interventions [133–135].

User-centered design principles emphasize including end users in the development process to ensure the chatbot meets their expectations and requirements [136].

6.7. Evidence Base and Research Gaps

Need for High-Quality Research. While the initial studies suggest the potential efficacy of AI chatbots in treating anxiety, more rigorous, large-scale RCTs are required to establish robust evidence [19,59,137].

Research should investigate long-term outcomes, compare their effectiveness with traditional therapies, and evaluate their impact across varied populations. Standardizing outcome measures and reporting methods can facilitate meta-analyses and systematic reviews [80].

Addressing Publication Bias. A bias toward positive findings can distort the perceived effectiveness of AI chatbots. Encouraging the publication of null or negative results is vital for maintaining a balanced understanding [75,138,139].

Open Science and Data Sharing: Promoting open science, including data sharing and transparent methodologies, may accelerate advancements in the field. Collaboration among researchers, clinicians, and developers can drive innovation and address common challenges [140–142].

6.8. Technological Advancements and Innovation

Integration of Emerging Technologies. Incorporating tools such as virtual reality (VR), augmented reality (AR), and wearable devices can expand AI chatbots' capabilities [143,144]. For instance, combining VR with chatbot interventions may offer immersive therapeutic experiences, especially useful in exposure therapy for anxiety disorders [145,146].

Interoperability and Integration with Health Systems. Ensuring AI chatbots can integrate with existing electronic health records (EHRs) and health information systems enhances continuity of care [147,148]. A seamless data exchange between chatbots and healthcare providers facilitates more coordinated interventions.

Artificial General Intelligence Considerations. As AI progresses toward artificial general intelligence (AGI), ethical and regulatory concerns become increasingly important. Proactive strategies are needed to address the potential implications of more autonomous and intelligent systems [149,150].

6.9. Sustainability and Scalability

Economic Models for Sustainable Deployment. Developing viable economic models is crucial to maintain AI chatbot interventions over the long term, covering expenses for development, maintenance, and updates [151]. Potential solutions include public–private partnerships, subscription-based services, or integration into national health systems.

Scalability Challenges. Expanding chatbot interventions to serve broader user populations raises technical and logistical challenges. The infrastructure must accommodate a higher demand without compromising performance or security [152]. Investing in scalable cloud-based solutions and robust backend architectures can support a broader deployment.

6.10. Legal and Liability Issues

Defining Professional Accountability. Establishing liability in cases where chatbot interventions result in adverse outcomes is complex. Clear guidelines on professional accountability for developers, providers, and clinicians are necessary [153].

Compliance with Medical Device Regulations. In some jurisdictions, AI chatbots for therapeutic purposes may be classified as medical devices, requiring adherence to regulatory

approval processes [154–156]. While these regulations ensure safety and efficacy, they may pose additional hurdles to innovation.

6.11. Future Perspectives

Collaborative Innovation. Progress depends on collaboration between technologists, clinicians, researchers, policymakers, and end users. Multidisciplinary teams can address the multifaceted challenges of implementing AI chatbots in mental health care [157].

Ethical AI Development. Centering ethical principles in AI development ensures that technological advancements reflect human values and societal needs. Guidelines like the European Commission's Ethical Guidelines for Trustworthy AI can inform responsible deployment [158,159].

Education and Training. Equipping healthcare professionals with knowledge about AI technologies and their mental health applications can expedite adoption and integration. Training programs can help practitioners harness chatbots effectively [160].

Patient Empowerment. Engaging patients in decision-making and providing them with meaningful control over their data and interventions fosters trust and adherence, ultimately enhancing clinical outcomes [161].

6.12. Integration with Existing Mental Health Care Frameworks

Integrating AI chatbots into current mental health care systems demands a holistic approach that addresses both technological and clinical considerations. Collaboration between AI developers and mental health professionals is vital to ensure that chatbots align with therapeutic goals and user needs.

Practical Strategies:

- *Collaborative Development and Training:* Chatbot development should incorporate expert input from clinicians, psychologists, and psychiatrists to ensure adherence to established therapeutic principles (e.g., CBT). Training mental health professionals in proper chatbot use can further support its adoption in clinical settings;
- *Supportive Role in Clinical Practice:* AI chatbots can supplement traditional therapy by reinforcing skills (e.g., mindfulness or stress management) between sessions and providing real-time support during moments of distress;
- *Integrated Care Pathways:* Embedding chatbots in care pathways allows clinicians to review data collected by the chatbot and customize treatment plans accordingly. This approach helps identify users in need of immediate professional intervention;
- *Enhancing User Trust:* Transparency regarding chatbot capabilities and limitations is crucial. Clear disclosure about the chatbot's non-human nature and its role as an adjunct rather than a standalone treatment builds user confidence;
- *Implementation in Underserved Areas:* AI chatbots can fill service gaps in low-resource or rural regions where human therapists are scarce. Governments and nonprofits can collaborate to deploy locally adapted chatbots that address cultural nuances;
- *Feedback Loops for Continuous Improvement:* Gathering feedback from users and clinicians helps refine chatbot features. Regular audits of chatbot performance, particularly in critical situations, support reliability and user satisfaction.

Integrating AI chatbots into existing mental health care frameworks can expand access, reduce clinicians' workloads, and improve patient outcomes. However, success depends on interdisciplinary collaboration, strong ethical guidelines, and a user-centered design. Future efforts should focus on scalable integration models adaptable to diverse healthcare systems and cultural contexts.

7. Conclusions

The integration of AI chatbots into mental health care marks a transformative advancement in addressing anxiety disorders, offering a scalable, accessible, and cost-effective alternative to traditional interventions. This review provides a comprehensive exploration of their evolution, efficacy, advantages, limitations, and potential future directions. Such insights underscore the growing relevance of AI-driven solutions in bridging critical gaps in mental health services globally.

AI chatbots have evolved from rule-based systems to advanced conversational agents that leverage NLP and machine learning algorithms [32,36]. These technologies enable the real-time delivery of evidence-based therapeutic interventions, such as CBT, while tailoring each session to individual user needs. Empirical evidence suggests that AI chatbots are effective in reducing anxiety symptoms, with benefits that extend to improved engagement and user satisfaction. Their capacity to operate beyond geographical or temporal restrictions makes them particularly valuable in contexts where access to mental health care is limited [97].

The key advantages of AI chatbots include affordability, immediate availability, and anonymity, which encourages openness and helps reduce the stigma associated with seeking mental health support [87,162,163]. Moreover, they can provide consistent support without the variability inherent in human interactions, making them a reliable adjunct to traditional therapy. By alleviating the burden on strained mental health systems, chatbots can enhance resource allocation efficiency and expand the overall capacity of mental health services [164,165].

Despite these benefits, several challenges persist. The lack of human empathy remains a primary limitation, as chatbots cannot replicate the emotional connection and nuanced understanding offered by human therapists. Ethical concerns surrounding user privacy and data security are also prominent, especially given the sensitive nature of mental health data. Technical hurdles—such as accurately interpreting complex emotions or cultural nuances—further constrain their effectiveness. Additionally, most chatbots are limited in scope, focusing primarily on specific interventions rather than offering the comprehensive approach often required in mental health care [166,167].

Addressing these limitations requires ongoing research and development. For example, enhancing the emotional intelligence of chatbots through affective computing and multimodal emotion recognition can improve their ability to respond empathetically [107]. Integrating chatbots into traditional mental health frameworks, where they can complement and augment the work of human therapists, offers a promising pathway [118]. Such an integration demands close collaboration between technologists, clinicians, and policymakers to ensure that chatbots are both effective and ethically deployed.

Ethical and regulatory considerations are critical to the responsible development and implementation of AI chatbots. Compliance with data protection regulations, such as the GDPR, is vital for safeguarding user privacy [82]. Ensuring transparency in data usage, obtaining informed consent, and empowering users with control over their information are foundational practices that must be upheld. Moreover, developing regulatory frameworks tailored to AI chatbots in mental health care can offer guidance on efficacy validation, professional accountability, and bias mitigation [49].

Future research should prioritize longitudinal studies to evaluate the sustained efficacy of AI chatbots in managing anxiety symptoms [14]. Robust evidence from large-scale RCTs with diverse populations is necessary to validate their clinical integration [76]. Additionally, investigations into cultural adaptation strategies can ensure that chatbots are sensitive to the linguistic, social, and cultural contexts of their users [168,169]. Personalization algorithms

can further boost user engagement by tailoring interventions to each individual's specific needs [170].

The convergence of AI chatbots with emerging technologies—such as virtual reality (VR), augmented reality (AR), and wearable devices—holds considerable promise [143,144]. These platforms can provide immersive therapeutic experiences and real-time biofeedback, thereby amplifying the impact of chatbot-based interventions. For instance, wearable devices that track physiological indicators (e.g., heart rate variability) can supply chatbots with actionable data, enabling more targeted and responsive interventions.

While the potential of AI chatbots is substantial, their effectiveness must be balanced with ethical considerations. Developers and providers must prioritize user well-being and ensure that chatbots contribute constructively to mental health care without causing harm [99]. Engaging stakeholders—including users, clinicians, ethicists, and policymakers—is essential to fostering responsible innovation and guaranteeing that the benefits of AI-driven mental health interventions are equitably distributed [171,172].

In conclusion, AI chatbots represent a highly promising adjunct to traditional mental health services, especially in addressing critical gaps in accessibility, affordability, and immediate care. By uniting technological innovation with ethical responsibility, these tools can enhance mental health outcomes for individuals with anxiety disorders worldwide. Continued research, interdisciplinary collaboration, and adherence to ethical principles will be pivotal in realizing the full potential of AI chatbots as a transformative force in mental health care.

Author Contributions: A.M.: Data Curation, Formal Analysis, Writing—Review and Editing; R.C.: Conceptualization, Methodology, Investigation, Writing—Original Draft Preparation; R.B.: Resources, Writing—Review and Editing; F.M.: Supervision, Project Administration, Validation. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the University of Oradea.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article. The authors confirm that they did not use Artificial Intelligence (AI) tools for the initial drafting of this article. However, ChatGPT-4 was employed for specific tasks such as formatting, copyediting, and improving readability in certain sections, including the abstract and conclusion. ChatGPT-4 was also utilized to ensure coherence between sections and assist in identifying any potential limitations of the work. The authors retained full control throughout the process, carefully reviewing all AI-generated suggestions to maintain the accuracy and integrity of the manuscript. The data input for the study and all revisions were provided and managed by the authors. Any contributions from ChatGPT-4 were thoroughly evaluated to ensure they did not introduce unintended content or inaccuracies. This disclosure reflects the authors' commitment to transparency in the use of AI tools, which is becoming increasingly relevant in academic research. The authors advocate the responsible use of AI technologies and believe that acknowledging their role in the writing process contributes to the ethical evolution of scholarly work.

Acknowledgments: The authors express sincere gratitude to the researchers and practitioners whose pioneering work in artificial intelligence and mental health has made this review possible. Their invaluable contributions and dedication have significantly advanced the understanding of AI chatbots in anxiety treatment, providing the foundation upon which this article is built.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Leal, P.S.; Bastos, W.D.G.; Félix, M.H.O.; de Lima, M.E.P.; dos Santos, M.V.; dos Santos, M.E.A.; Randau, K.P. Anxiety and its relationship with the integrative practice of aromatherapy. In *The Evolution of Research in Health Sciences*; Seven Editora: São José dos Pinhais, Brazil, 2024; pp. 389–397. [CrossRef]
2. Krzyzaniak, N.; Greenwood, H.; Scott, A.M.; Peiris, R.; Cardona, M.; Clark, J.; Glasziou, P. The effectiveness of telehealth versus face-to face interventions for anxiety disorders: A systematic review and meta-analysis. *J. Telemed. Telecare* **2024**, *30*, 250–261. [CrossRef] [PubMed]
3. Olatunji, B.O.; Cisler, J.M.; Tolin, D.F. Quality of life in the anxiety disorders: A meta-analytic review. *Clin. Psychol. Rev.* **2007**, *27*, 572–581. [CrossRef] [PubMed]
4. Rapaport, M.H.; Clary, C.; Fayyad, R.; Endicott, J. Quality-of-life impairment in depressive and anxiety disorders. *Am. J. Psychiatry* **2005**, *162*, 1171–1178. [CrossRef]
5. Mendlowicz, M.V.; Stein, M.B. Quality of life in individuals with anxiety disorders. *Am. J. Psychiatry* **2000**, *157*, 669–682. [CrossRef]
6. Tzavela, E.C.; Mitskidou, P.; Mertika, A.; Stalikas, A.; Kasvikis, Y. Treatment engagement in the early phase of cognitive-behavior therapy for panic disorder: A grounded theory analysis of patient experience. *Psychother. Res.* **2018**, *28*, 842–860. [CrossRef] [PubMed]
7. Nicoară, N.D.; Marian, P.; Petriș, A.O.; Delcea, C.; Manole, F. A review of the role of cognitive-behavioral therapy on anxiety disorders of children and adolescents. *Pharmacophore* **2023**, *14*, 35–39. [CrossRef]
8. Dunlop, B.W.; Davis, P.G. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: A review. *Prim. Care Companion J. Clin. Psychiatry* **2008**, *10*, 222–228. [CrossRef] [PubMed]
9. Andrade, L.H.; Alonso, J.; Mneimneh, Z.; Wells, J.; Al-Hamzawi, A.; Borges, G.; Bromet, E.; Bruffaerts, R.; De Girolamo, G.; De Graaf, R. Barriers to mental health treatment: Results from the WHO World Mental Health surveys. *Psychol. Med.* **2014**, *44*, 25. [CrossRef]
10. Manole, F.; Marian, P.; Mekeress, G.M.; Voiță-Mekeress, F. Systematic review of the effect of aging on health costs. *Arch. Pharm. Pract.* **2023**, *14*, 58–61. [CrossRef]
11. Corrigan, P.W.; Druss, B.G.; Perlick, D.A. The impact of mental illness stigma on seeking and participating in mental health care. *Psychol. Sci. Public Interest* **2014**, *15*, 37–70. [CrossRef] [PubMed]
12. Casu, M.; Triscari, S.; Battiato, S.; Guarnera, L.; Caponnetto, P. AI Chatbots for Mental Health: A Scoping Review of Effectiveness, Feasibility, and Applications. *Appl. Sci.* **2024**, *14*, 23. [CrossRef]
13. Boucher, E.M.; Harake, N.R.; Ward, H.E.; Stoeckl, S.E.; Vargas, J.; Minkel, J.; Parks, A.C.; Zilca, R. Artificially intelligent chatbots in digital mental health interventions: A review. *Expert Rev. Med. Devices* **2021**, *18*, 37–49. [CrossRef]
14. Abd-Alrazaq, A.A.; Rababeh, A.; Alajlani, M.; Bewick, B.M.; Househ, M. Effectiveness and safety of using chatbots to improve mental health: Systematic review and meta-analysis. *J. Med. Internet Res.* **2020**, *22*, 17. [CrossRef] [PubMed]
15. Vaidyam, A.N.; Wisniewski, H.; Halamka, J.D.; Kashavan, M.S.; Torous, J.B. Chatbots and conversational agents in mental health: A review of the psychiatric landscape. *Can. J. Psychiatry* **2019**, *64*, 456–464. [CrossRef] [PubMed]
16. Liu, B.; Sundar, S.S. Should machines express sympathy and empathy? Experiments with a health advice chatbot. *Cyberpsychol. Behav. Soc. Netw.* **2018**, *21*, 625–636. [CrossRef] [PubMed]
17. Seitz, L. Artificial empathy in healthcare chatbots: Does it feel authentic? *Comput. Hum. Behav. Artif. Hum.* **2024**, *2*, 17. [CrossRef]
18. Fulmer, R.; Joerin, A.; Gentile, B.; Lakerink, L.; Rauws, M. Using psychological artificial intelligence (Tess) to relieve symptoms of depression and anxiety: Randomized controlled trial. *JMIR Ment. Health* **2018**, *5*, 15. [CrossRef] [PubMed]
19. Manole, A.; Cârciumar, R.; Brînzaș, R.; Manole, F. Harnessing AI in Anxiety Management: A Chatbot-Based Intervention for Personalized Mental Health Support. *Information* **2024**, *15*, 768. [CrossRef]
20. Abd-Alrazaq, A.A.; Alajlani, M.; Ali, N.; Denecke, K.; Bewick, B.M.; Househ, M. Perceptions and opinions of patients about mental health chatbots: Scoping review. *J. Med. Internet Res.* **2021**, *23*, e17828. [CrossRef] [PubMed]
21. Rahsepar Meadi, M.; Bernstein, J.S.; Batelaan, N.; van Balkom, A.J.; Metselaar, S. Does a lack of emotions make chatbots unfit to be psychotherapists? *Bioethics* **2024**, *38*, 503–510. [CrossRef] [PubMed]
22. Giordani, J. Mitigating Chatbots AI Data Privacy Violations in the Banking Sector: A Qualitative Grounded Theory Study. *Eur. J. Appl. Sci. Eng. Technol.* **2024**, *2*, 14–65. [CrossRef] [PubMed]
23. Banerjee, S.; Agarwal, A.; Bar, A.K. Securing Well-Being: Exploring Security Protocols and Mitigating Risks in AI-Driven Mental Health Chatbots for Employees. *Am. J. Comput. Sci. Technol.* **2024**, *7*, 1–8. [CrossRef]
24. Sutton, J. Revolutionizing AI Therapy: The Impact on Mental Health Care. Available online: <https://positivepsychology.com/ai-therapy/> (accessed on 13 October 2024).
25. Nazi, Z.A.; Peng, W. Large language models in healthcare and medical domain: A review. In Proceedings of the Informatics, Poprad, Slovak Republic, 13–15 November 2024; p. 57.
26. Weizenbaum, J. ELIZA—A computer program for the study of natural language communication between man and machine. *Commun. ACM* **1966**, *9*, 36–45. [CrossRef]

27. Colby, K.M. Modeling a paranoid mind. *Behav. Brain Sci.* **1981**, *4*, 46. [CrossRef]
28. Colby, K.M. *Artificial Paranoia: A Computer Simulation of Paranoid Processes*; Pergamon Press: New York, NY, USA, 1975; p. 126. [CrossRef]
29. Hirschberg, J.; Manning, C.D. Advances in natural language processing. *Science* **2015**, *349*, 261–266. [CrossRef] [PubMed]
30. Russell, S.J.; Norvig, P. *Artificial Intelligence: A Modern Approach*; Pearson: London, UK, 2016.
31. Luxton, D.D.; Kayl, R.A.; Mishkind, M.C. mHealth data security: The need for HIPAA-compliant standardization. *Telemed. e-Health* **2012**, *18*, 284–288. [CrossRef]
32. Inkster, B.; Kadaba, M.; Subramanian, V. Understanding the impact of an AI-enabled conversational agent mobile app on users' mental health and wellbeing with a self-reported maternal event: A mixed method real-world data mHealth study. *Front. Glob. Women's Health* **2023**, *4*, 10. [CrossRef] [PubMed]
33. Free, C.; Phillips, G.; Watson, L.; Galli, L.; Felix, L.; Edwards, P.; Patel, V.; Haines, A. The effectiveness of mobile-health technologies to improve health care service delivery processes: A systematic review and meta-analysis. *PLoS Med.* **2013**, *10*, 26. [CrossRef]
34. Beck, J.S. *Cognitive Behavior Therapy: Basics and Beyond*; Guilford Publications: New York, NY, USA, 2020.
35. Knapp, P.; Beck, A.T. Cognitive therapy: Foundations, conceptual models, applications and research. *Braz. J. Psychiatry* **2008**, *30*, 54–64. [CrossRef]
36. Fitzpatrick, K.K.; Darcy, A.; Vierhile, M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): A randomized controlled trial. *JMIR Ment. Health* **2017**, *4*, 11. [CrossRef] [PubMed]
37. Durden, E.; Pirner, M.C.; Rapoport, S.J.; Williams, A.; Robinson, A.; Forman-Hoffman, V.L. Changes in stress, burnout, and resilience associated with an 8-week intervention with relational agent "Woebot". *Internet Interv.* **2023**, *33*, 11. [CrossRef] [PubMed]
38. LeCun, Y.; Bengio, Y.; Hinton, G. Deep learning. *Nature* **2015**, *521*, 436–444. [CrossRef] [PubMed]
39. Inkster, B.; Sarda, S.; Subramanian, V. An empathy-driven, conversational artificial intelligence agent (Wysa) for digital mental well-being: Real-world data evaluation mixed-methods study. *JMIR Mhealth Uhealth* **2018**, *6*, 14. [CrossRef] [PubMed]
40. Taciuc, I.-A.; Dumitru, M.; Vrinceanu, D.; Gherghe, M.; Manole, F.; Marinescu, A.; Serboiu, C.; Neagos, A.; Costache, A. Applications and challenges of neural networks in otolaryngology. *Biomed. Rep.* **2024**, *20*, 92. [CrossRef]
41. Calvo, R.A.; Milne, D.N.; Hussain, M.S.; Christensen, H. Natural language processing in mental health applications using non-clinical texts. *Nat. Lang. Eng.* **2017**, *23*, 649–685. [CrossRef]
42. Lee, M.-C.; Chiang, S.-Y.; Yeh, S.-C.; Wen, T.-F. Study on emotion recognition and companion Chatbot using deep neural network. *Multimed. Tools Appl.* **2020**, *79*, 19629–19657. [CrossRef]
43. Roy-Byrne, P.P.; Davidson, K.W.; Kessler, R.C.; Asmundson, G.J.; Goodwin, R.D.; Kubzansky, L.; Lydiard, R.B.; Massie, M.J.; Katon, W.; Laden, S.K. Anxiety disorders and comorbid medical illness. *Gen. Hosp. Psychiatry* **2008**, *30*, 208–225. [CrossRef] [PubMed]
44. Ly, K.H.; Ly, A.-M.; Andersson, G. A fully automated conversational agent for promoting mental well-being: A pilot RCT using mixed methods. *Internet Interv.* **2017**, *10*, 39–46. [CrossRef]
45. Luxton, D.D. Artificial intelligence in psychological practice: Current and future applications and implications. *Prof. Psychol. Res. Pract.* **2014**, *45*, 9. [CrossRef]
46. Patel, V.; Chowdhary, N.; Rahman, A.; Verdeli, H. Improving access to psychological treatments: Lessons from developing countries. *Behav. Res. Ther.* **2011**, *49*, 523–528. [CrossRef] [PubMed]
47. Parcesepe, A.M.; Bernard, C.; Agler, R.; Ross, J.; Yotebieng, M.; Bass, J.; Kwobah, E.; Adedimeji, A.; Goulet, J.; Althoff, K.N. Mental health and HIV: Research priorities related to the implementation and scale up of 'treat all' in sub-Saharan Africa. *J. Virus Erad.* **2018**, *4*, 16–25. [CrossRef] [PubMed]
48. U.S. Food and Drug Administration. *Policy for Device Software Functions and Mobile Medical Applications*; Food and Drug Administration: Montgomery, AL, USA, 2019.
49. Mittelstadt, B.D.; Allo, P.; Taddeo, M.; Wachter, S.; Floridi, L. The ethics of algorithms: Mapping the debate. *Big Data Soc.* **2016**, *3*, 21. [CrossRef]
50. Luxton, D.D. Recommendations for the ethical use and design of artificial intelligent care providers. *Artif. Intell. Med.* **2014**, *62*, 1–10. [CrossRef] [PubMed]
51. European Parliament; Council of the European Union. General Data Protection Regulation (GDPR). *Off. J. Eur. Union* **2016**, 1–88. Available online: <https://eur-lex.europa.eu/eli/reg/2016/679/oj/eng> (accessed on 4 December 2024).
52. Alvarez-Jimenez, M.; Alcazar-Corcoles, M.A.; Gonzalez-Blanch, C.; Bendall, S.; McGorry, P.D.; Gleeson, J.F. Online, social media and mobile technologies for psychosis treatment: A systematic review on novel user-led interventions. *Schizophr. Res.* **2014**, *156*, 96–106. [CrossRef] [PubMed]

53. Li, H.; Zhang, R.; Lee, Y.-C.; Kraut, R.E.; Mohr, D.C. Systematic review and meta-analysis of AI-based conversational agents for promoting mental health and well-being. *Digit. Med.* **2023**, *6*, 14. [[CrossRef](#)] [[PubMed](#)]
54. Gooding, P. Mapping the rise of digital mental health technologies: Emerging issues for law and society. *Int. J. Law Psychiatry* **2019**, *67*, 26. [[CrossRef](#)]
55. Chen, H.-L.; Vicki Widarso, G.; Sutrisno, H. A chatbot for learning Chinese: Learning achievement and technology acceptance. *J. Educ. Comput. Res.* **2020**, *58*, 1161–1189. [[CrossRef](#)]
56. Picard, R.W. Affective computing: From laughter to IEEE. *IEEE Trans. Affect. Comput.* **2010**, *1*, 11–17. [[CrossRef](#)]
57. Bickmore, T.W.; Picard, R.W. Establishing and maintaining long-term human-computer relationships. *ACM Trans. Comput. Hum. Interact.* **2005**, *12*, 293–327. [[CrossRef](#)]
58. Richards, D.; Richardson, T. Computer-based psychological treatments for depression: A systematic review and meta-analysis. *Clin. Psychol. Rev.* **2012**, *32*, 329–342. [[CrossRef](#)] [[PubMed](#)]
59. Mohr, D.C.; Schueller, S.M.; Riley, W.T.; Brown, C.H.; Cuijpers, P.; Duan, N.; Kwasny, M.J.; Stiles-Shields, C.; Cheung, K. Trials of intervention principles: Evaluation methods for evolving behavioral intervention technologies. *J. Med. Internet Res.* **2015**, *17*, 14. [[CrossRef](#)] [[PubMed](#)]
60. Renteria, K.; Nguyen, H.; Koh, G.Y. The role of vitamin D in depression and anxiety disorders: A review of the literature. *Nutr. Neurosci.* **2024**, *27*, 262–270. [[CrossRef](#)]
61. Voiță-Mekereș, F.; Manole, F.; Voiță, I.B.; Marian, P. The Role of Food Biochemistry in the Control and Prevention of Nervous System Diseases. *J. Biochem. Technol.* **2023**, *14*, 112–116. [[CrossRef](#)]
62. Bourre, J.-M. Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 1: Micronutrients. *J. Nutr. Health Aging* **2006**, *10*, 9.
63. Fantini, C.; Corinaldesi, C.; Lenzi, A.; Migliaccio, S.; Crescioli, C. Vitamin D as a Shield against Aging. *Int. J. Mol. Sci.* **2023**, *24*, 4546. [[CrossRef](#)]
64. Trifan, D.F.; Tirla, A.G.; Mos, C.; Danciu, A.; Bodog, F.; Manole, F.; Ghitea, T.C. Involvement of Vitamin D3 in the Aging Process According to Sex. *Cosmetics* **2023**, *10*, 114. [[CrossRef](#)]
65. Bocheva, G.; Slominski, R.M.; Slominski, A.T. The impact of vitamin D on skin aging. *Int. J. Mol. Sci.* **2021**, *22*, 9097. [[CrossRef](#)] [[PubMed](#)]
66. Trifan, D.F.; Tirla, A.G.; Moldovan, A.F.; Moș, C.; Bodog, F.; Maghiar, T.T.; Manole, F.; Ghitea, T.C. Can vitamin D levels alter the effectiveness of short-term facelift interventions? *Healthcare* **2023**, *11*, 1490. [[CrossRef](#)] [[PubMed](#)]
67. Nicol, G.; Wang, R.; Graham, S.; Dodd, S.; Garbutt, J. Chatbot-delivered cognitive behavioral therapy in adolescents with depression and anxiety during the COVID-19 pandemic: Feasibility and acceptability study. *JMIR Form. Res.* **2022**, *6*, 13. [[CrossRef](#)]
68. McDaid, D.; Park, A.-L.; Wahlbeck, K. The economic case for the prevention of mental illness. *Annu. Rev. Public Health* **2019**, *40*, 373–389. [[CrossRef](#)]
69. Alfnsson, S.; Wallin, E.; Maathz, P. Factor structure and validity of the Depression, Anxiety and Stress Scale-21 in Swedish translation. *J. Psychiatr. Ment. Health Nurs.* **2017**, *24*, 154–162. [[CrossRef](#)]
70. Dwight, A.R.; Briesch, A.M.; Hoffman, J.A.; Rutt, C. Systematic Review of the Psychometric Evidence Supporting Use of the Depression Anxiety Stress Scales, Short Form (DASS-21) with Youth. *Child & Youth Care Forum* **2024**, *53*, 1235–1250. [[CrossRef](#)]
71. Dwight, A.R. Exploring the Utility of the Depression Anxiety and Stress Scales, Short Form (DASS-21) as a Progress Monitoring Tool for Youth. Ph.D. Thesis, Northeastern University, Boston, MA, USA, 2022.
72. Danieli, M.; Ciulli, T.; Mousavi, S.M.; Silvestri, G.; Barbato, S.; Di Natale, L.; Riccardi, G. Assessing the impact of conversational artificial intelligence in the treatment of stress and anxiety in aging adults: Randomized controlled trial. *JMIR Ment. Health* **2022**, *9*, 15. [[CrossRef](#)] [[PubMed](#)]
73. Perski, O.; Blandford, A.; West, R.; Michie, S. Conceptualising engagement with digital behaviour change interventions: A systematic review using principles from critical interpretive synthesis. *Transl. Behav. Med.* **2017**, *7*, 254–267. [[CrossRef](#)]
74. Crawford, A.; Serhal, E. Digital health equity and COVID-19: The innovation curve cannot reinforce the social gradient of health. *J. Med. Internet Res.* **2020**, *22*, 5. [[CrossRef](#)]
75. Dwan, K.; Gamble, C.; Williamson, P.R.; Kirkham, J.J.; Group, R.B. Systematic review of the empirical evidence of study publication bias and outcome reporting bias—An updated review. *PLoS ONE* **2013**, *8*, e66844. [[CrossRef](#)] [[PubMed](#)]
76. Firth, J.; Torous, J.; Nicholas, J.; Carney, R.; Pratap, A.; Rosenbaum, S.; Sarris, J. The efficacy of smartphone-based mental health interventions for depressive symptoms: A meta-analysis of randomized controlled trials. *World Psychiatry* **2017**, *16*, 287–298. [[CrossRef](#)]
77. Liu, Y.-I.; Yan, W.; Hu, B.; Li, Z.; Lai, Y.L. Effects of personalization and source expertise on users' health beliefs and usage intention toward health chatbots: Evidence from an online experiment. *Digit. Health* **2022**, *8*, 18. [[CrossRef](#)]
78. Gaggioli, A.; Riva, G. From mobile mental health to mobile wellbeing: Opportunities and challenges. *Stud. Health Technol. Inform.* **2013**, *20*, 141–147.

79. Provoost, S.; Lau, H.M.; Ruwaard, J.; Riper, H. Embodied conversational agents in clinical psychology: A scoping review. *J. Med. Internet Res.* **2017**, *19*, e151. [CrossRef]
80. Baumel, A.; Muench, F.; Edan, S.; Kane, J.M. Objective user engagement with mental health apps: Systematic search and panel-based usage analysis. *J. Med. Internet Res.* **2019**, *21*, e14567. [CrossRef] [PubMed]
81. Schillings, C.; Meißner, E.; Erb, B.; Bendig, E.; Schultchen, D.; Pollatos, O. Effects of a Chatbot-Based Intervention on Stress and Health-Related Parameters in a Stressed Sample: Randomized Controlled Trial. *JMIR Ment Health* **2024**, *11*, e50454. [CrossRef] [PubMed]
82. Voigt, P.; Von dem Bussche, A. *The EU General Data Protection Regulation (GDPR)*; Springer: Berlin/Heidelberg, Germany, 2017; Volume 10, p. 339.
83. Cross, S.; Nicholas, J.; Mangelsdorf, S.; Valentine, L.; Baker, S.; McGorry, P.; Gleeson, J.; Alvarez-Jimenez, M. Developing a Theory of Change for a Digital Youth Mental Health Service (Moderated Online Social Therapy): Mixed Methods Knowledge Synthesis Study. *JMIR Form. Res.* **2023**, *7*, e49846. [CrossRef] [PubMed]
84. Palermo, T.M.; de la Vega, R.; Murray, C.; Law, E.; Zhou, C. A digital health psychological intervention (WebMAP Mobile) for children and adolescents with chronic pain: Results of a hybrid effectiveness-implementation stepped-wedge cluster randomized trial. *Pain* **2020**, *161*, 2763–2774. [CrossRef] [PubMed]
85. Sue, S.; Zane, N. The role of culture and cultural techniques in psychotherapy: A critique and reformulation. *Am. Psychol.* **1987**, *42*, 37. [CrossRef]
86. Mohammad Amini, M.; Jesus, M.; Fanaei Sheikholeslami, D.; Alves, P.; Hassanzadeh Benam, A.; Hariri, F. Artificial intelligence ethics and challenges in healthcare applications: A comprehensive review in the context of the European GDPR mandate. *Mach. Learn. Knowl. Extr.* **2023**, *5*, 1023–1035. [CrossRef]
87. Andersson, G.; Titov, N. Advantages and limitations of Internet-based interventions for common mental disorders. *World Psychiatry* **2014**, *13*, 4–11. [CrossRef]
88. Torous, J.; Myrick, K.J.; Rauseo-Ricupero, N.; Firth, J. Digital mental health and COVID-19: Using technology today to accelerate the curve on access and quality tomorrow. *JMIR Ment. Health* **2020**, *7*, e18848. [CrossRef]
89. Wasim, A.; Truong, J.; Bakshi, S.; Majid, U. A systematic review of fear, stigma, and mental health outcomes of pandemics. *J. Ment. Health* **2023**, *32*, 920–934. [CrossRef]
90. Zaha, D.C.; Ilea, C.D.N.; Dorobanțu, F.R.; Pantis, C.; Pop, O.N.; Dascal, D.G.; Dorobanțu, C.D.; Manole, F. The Impact of SARS-CoV-2 Pandemic on Antibiotic Prescriptions and Resistance in a University Hospital from Romania. *Antibiotics* **2024**, *13*, 477. [CrossRef]
91. Van Ameringen, M.; Turna, J.; Khalesi, Z.; Pullia, K.; Patterson, B. There is an app for that! The current state of mobile applications (apps) for DSM-5 obsessive-compulsive disorder, posttraumatic stress disorder, anxiety and mood disorders. *Depress. Anxiety* **2017**, *34*, 526–539. [CrossRef] [PubMed]
92. Gulliver, A.; Griffiths, K.M.; Christensen, H. Perceived barriers and facilitators to mental health help-seeking in young people: A systematic review. *BMC Psychiatry* **2010**, *10*, 1–9. [CrossRef] [PubMed]
93. Pretorius, C.; Chambers, D.; Coyle, D. Young people’s online help-seeking and mental health difficulties: Systematic narrative review. *J. Med. Internet Res.* **2019**, *21*, e13873. [CrossRef]
94. Cuijpers, P.; Marks, I.M.; van Straten, A.; Cavanagh, K.; Gega, L.; Andersson, G. Computer-aided psychotherapy for anxiety disorders: A meta-analytic review. *Cogn. Behav. Ther.* **2009**, *38*, 66–82. [CrossRef] [PubMed]
95. Thase, M.E.; Wright, J.H.; Eells, T.D.; Barrett, M.S.; Wisniewski, S.R.; Balasubramani, G.; McCrone, P.; Brown, G.K. Improving the efficiency of psychotherapy for depression: Computer-assisted versus standard CBT. *Am. J. Psychiatry* **2018**, *175*, 242–250. [CrossRef]
96. Elliott, R.; Bohart, A.C.; Watson, J.C.; Greenberg, L.S. Empathy. *Psychotherapy* **2011**, *48*, 43. [CrossRef]
97. Hoermann, S.; McCabe, K.L.; Milne, D.N.; Calvo, R.A. Application of synchronous text-based dialogue systems in mental health interventions: Systematic review. *J. Med. Internet Res.* **2017**, *19*, e267. [CrossRef]
98. Martinez-Martin, N.; Kreitmair, K. Ethical Issues for Direct-to-Consumer Digital Psychotherapy Apps: Addressing Accountability, Data Protection, and Consent. *JMIR Ment. Health* **2018**, *5*, e32. [CrossRef] [PubMed]
99. Floridi, L.; Cows, J. A Unified Framework of Five Principles for AI in Society. In *Machine Learning and the City: Applications in Architecture and Urban Design*; Wiley-Blackwell: Hoboken, NJ, USA, 2022; pp. 535–545.
100. Dale, R. The return of the chatbots. *Nat. Lang. Eng.* **2016**, *22*, 811–817. [CrossRef]
101. Smith, A. Older Adults and Technology Use. Pew Research Center. 2014, p. 27. Available online: <http://www.pewinternet.org/2014/04/03/older-adults-and-technology-use/> (accessed on 4 December 2024).
102. Berry, N.; Lobban, F.; Emsley, R.; Bucci, S. Acceptability of interventions delivered online and through mobile phones for people who experience severe mental health problems: A systematic review. *J. Med. Internet Res.* **2016**, *18*, e121. [CrossRef]
103. Seabrook, E.M.; Kern, M.L.; Rickard, N.S. Social networking sites, depression, and anxiety: A systematic review. *JMIR Ment. Health* **2016**, *3*, e5842. [CrossRef] [PubMed]

104. Wen, B.; Norel, R.; Liu, J.; Stappenbeck, T.; Zulkernine, F.; Chen, H. Leveraging Large Language Models for Patient Engagement: The Power of Conversational AI in Digital Health. *arXiv* **2024**, arXiv:2406.13659.
105. McTear, M.F.; Callejas, Z.; Griol, D. *The Conversational Interface*; Springer: Berlin/Heidelberg, Germany, 2016; Volume 6.
106. Mittelstadt, B. Ethics of the health-related internet of things: A narrative review. *Ethics Inf. Technol.* **2017**, *19*, 157–175. [[CrossRef](#)]
107. Mohr, D.C.; Weingardt, K.R.; Reddy, M.; Schueller, S.M. Three problems with current digital mental health research... and three things we can do about them. *Psychiatr. Serv.* **2017**, *68*, 427–429. [[CrossRef](#)] [[PubMed](#)]
108. Ospina-Pinillos, L.; Davenport, T.A.; Ricci, C.S.; Milton, A.C.; Scott, E.M.; Hickie, I.B. Developing a mental health eClinic to improve access to and quality of mental health care for young people: Using participatory design as research methodologies. *J. Med. Internet Res.* **2018**, *20*, e188. [[CrossRef](#)]
109. Calvo, R.A.; D’Mello, S.; Gratch, J.M.; Kappas, A. *The Oxford handbook of affective computing*; Oxford University Press: New York, NY, USA, 2015.
110. Chakraborty, C.; Bhattacharya, M.; Pal, S.; Lee, S.-S. From machine learning to deep learning: Advances of the recent data-driven paradigm shift in medicine and healthcare. *Curr. Res. Biotechnol.* **2024**, *7*, 100164. [[CrossRef](#)]
111. Rani, M.U.; Stalin, M.S.; Kumar, V.; Kumar, C.A.; Sandhyarani, M.; Kosuri, U. Advancing Emotional Intelligence in Chatbots through Deep Learning: A Framework for Real-Time Sentiment and Emotion Recognition. *Front. Health Inform.* **2024**, *13*, 7880–7897.
112. Bilquise, G.; Ibrahim, S.; Shaalan, K. Emotionally intelligent chatbots: A systematic literature review. *Hum. Behav. Emerg. Technol.* **2022**, *2022*, 9601630. [[CrossRef](#)]
113. Huang, M.-H.; Rust, R.T. Artificial intelligence in service. *J. Serv. Res.* **2018**, *21*, 155–172. [[CrossRef](#)]
114. D’mello, S.K.; Kory, J. A review and meta-analysis of multimodal affect detection systems. *ACM Comput. Surv.* **2015**, *47*, 1–36. [[CrossRef](#)]
115. Lee, S.; Yoon, J.; Cho, Y.; Chun, J. A systematic review of chatbot-assisted interventions for substance use. *Front. Psychiatry* **2024**, *15*, 1456689. [[CrossRef](#)] [[PubMed](#)]
116. Naslund, J.A.; Aschbrenner, K.A.; Araya, R.; Marsch, L.A.; Unützer, J.; Patel, V.; Bartels, S.J. Digital technology for treating and preventing mental disorders in low-income and middle-income countries: A narrative review of the literature. *Lancet Psychiatry* **2017**, *4*, 486–500. [[CrossRef](#)]
117. Bower, P.; Gilbody, S.; Richards, D.; Fletcher, J.; Sutton, A. Collaborative care for depression in primary care: Making sense of a complex intervention: Systematic review and meta-regression. *Br. J. Psychiatry* **2006**, *189*, 484–493. [[CrossRef](#)] [[PubMed](#)]
118. Topol, E.J. High-performance medicine: The convergence of human and artificial intelligence. *Nat. Med.* **2019**, *25*, 44–56. [[CrossRef](#)] [[PubMed](#)]
119. Möllmann, N.R.; Mirbabaie, M.; Stieglitz, S. Is it alright to use artificial intelligence in digital health? A systematic literature review on ethical considerations. *Health Inform. J.* **2021**, *27*, 14604582211052391. [[CrossRef](#)]
120. Li, F.; Ruijs, N.; Lu, Y. Ethics & AI: A systematic review on ethical concerns and related strategies for designing with AI in healthcare. *AI* **2022**, *4*, 28–53. [[CrossRef](#)]
121. Nebeker, C.; Torous, J.; Bartlett Ellis, R.J. Building the case for actionable ethics in digital health research supported by artificial intelligence. *BMC Med.* **2019**, *17*, 1–7. [[CrossRef](#)] [[PubMed](#)]
122. Mehrabi, N.; Morstatter, F.; Saxena, N.; Lerman, K.; Galstyan, A. A survey on bias and fairness in machine learning. *ACM Comput. Surv.* **2021**, *54*, 1–35. [[CrossRef](#)]
123. Friedman, B.; Hendry, D.G. *Value Sensitive Design: Shaping Technology with Moral Imagination*; MIT Press: Cambridge, MA, USA, 2019.
124. Nikolinakos, N.T. A European Approach to Excellence and Trust: The 2020 White Paper on Artificial Intelligence. In *EU Policy and Legal Framework for Artificial Intelligence, Robotics and Related Technologies—The AI Act*; Springer: Berlin/Heidelberg, Germany, 2023; pp. 211–280.
125. Estella, A. Trust in Artificial Intelligence: Analysis of the European Commission Proposal for a Regulation of Artificial Intelligence. *Ind. J. Glob. Leg. Stud.* **2023**, *30*, 39–64. [[CrossRef](#)]
126. Odeh, A.; Keshta, I.; Al-Haija, Q.A. Analysis of blockchain in the healthcare sector: Application and issues. *Symmetry* **2022**, *14*, 1760. [[CrossRef](#)]
127. Tagde, P.; Tagde, S.; Bhattacharya, T.; Tagde, P.; Chopra, H.; Akter, R.; Kaushik, D.; Rahman, M.H. Blockchain and artificial intelligence technology in e-Health. *Environ. Sci. Pollut. Res.* **2021**, *28*, 52810–52831. [[CrossRef](#)] [[PubMed](#)]
128. Linardon, J.; Cuijpers, P.; Carlbring, P.; Messer, M.; Fuller-Tyszkiewicz, M. The efficacy of app-supported smartphone interventions for mental health problems: A meta-analysis of randomized controlled trials. *World Psychiatry* **2019**, *18*, 325–336. [[CrossRef](#)]
129. Kitayama, S.; Salvador, C.E. Cultural psychology: Beyond east and west. *Annu. Rev. Psychol.* **2024**, *75*, 495–526. [[CrossRef](#)]
130. Buki, L.P.; Johnson, J.M.Q.; Knight, K.; Walton, A. “Cultural and conceptual knowledge”: Reformulation and conceptual analysis of a key component of the health literacy model. *Soc. Sci. Med.* **2024**, *12*, 117150. [[CrossRef](#)]

131. Hulls, P.M.; Richmond, R.C.; Martin, R.M.; Chavez-Ugalde, Y.; de Vocht, F. Workplace interventions that aim to improve employee health and well-being in male-dominated industries: A systematic review. *Occup. Environ. Med.* **2022**, *79*, 77–87. [CrossRef]
132. Stratton, E.; Player, M.J.; Glozier, N. Online mental health training program for male-dominated organisations: A pre-post pilot study assessing feasibility, usability, and preliminary effectiveness. *Int. Arch. Occup. Environ. Health* **2023**, *96*, 641–649. [CrossRef] [PubMed]
133. Laranjo, L.; Ding, D.; Heleno, B.; Kocaballi, B.; Quiroz, J.C.; Tong, H.L.; Chahwan, B.; Neves, A.L.; Gabarron, E.; Dao, K.P. Do smartphone applications and activity trackers increase physical activity in adults? Systematic review, meta-analysis and meta-regression. *Br. J. Sports Med.* **2021**, *55*, 422–432. [CrossRef] [PubMed]
134. Singh, B.; Olds, T.; Curtis, R.; Dumuid, D.; Virgara, R.; Watson, A.; Szeto, K.; O'Connor, E.; Ferguson, T.; Eglitis, E. Effectiveness of physical activity interventions for improving depression, anxiety and distress: An overview of systematic reviews. *Br. J. Sports Med.* **2023**, *57*, 1203–1209. [CrossRef]
135. Bancsik, K.; Ilea, C.D.N.; Daina, M.D.; Bancsik, R.; Şuteu, C.L.; Bîrsan, S.D.; Manole, F.; Daina, L.G. Comparative Analysis of Patient Satisfaction Surveys—A Crucial Role in Raising the Standard of Healthcare Services. *Healthcare* **2023**, *11*, 2878. [CrossRef]
136. Pinho, L.G.d.; Lopes, M.J.; Correia, T.; Sampaio, F.; Arco, H.R.d.; Mendes, A.; Marques, M.d.C.; Fonseca, C. Patient-centered care for patients with depression or anxiety disorder: An integrative review. *J. Pers. Med.* **2021**, *11*, 776. [CrossRef] [PubMed]
137. Wong, A.W.; Fong, M.W.; Munsell, E.G.; Metts, C.L.; Lee, S.I.; Nicol, G.E.; DePaul, O.; Tomazin, S.E.; Kaufman, K.J.; Mohr, D.C. Using intervention mapping and behavior change techniques to develop a digital intervention for self-management in stroke: Development study. *JMIR Hum. Factors* **2023**, *10*, e45099. [CrossRef]
138. Ouyang, F.; Zheng, L.; Jiao, P. Artificial intelligence in online higher education: A systematic review of empirical research from 2011 to 2020. *Educ. Inf. Technol.* **2022**, *27*, 7893–7925. [CrossRef]
139. Mavrogiorgos, K.; Kiourtis, A.; Mavrogiorgou, A.; Menychtas, A.; Kyriazis, D. Bias in Machine Learning: A Literature Review. *Appl. Sci.* **2024**, *14*, 8860. [CrossRef]
140. Bejalwar, S.A. Embracing Open Science and Open Access Initiatives: A Comprehensive Review. In *Proceedings of the Recent Advancements in Science Technology*; Sai Jyoti Publication: Nagpur, India, 2024; pp. 112–117. ISBN 978-81-19931-25-5.
141. Hulsén, T. Sharing is caring—Data sharing initiatives in healthcare. *Int. J. Environ. Res. Public Health* **2020**, *17*, 3046. [CrossRef]
142. Wolfram, D.; Wang, P.; Hembree, A.; Park, H. Open peer review: Promoting transparency in open science. *Scientometrics* **2020**, *125*, 1033–1051. [CrossRef]
143. Riva, G. Positive Technology in the Metaverse: Experiential Technologies Meet Mental Wellbeing. In *Proceedings of the Positive Technology International Conference 2023 Positive Technology: Possible Synergies between Emerging Technologies and Positive Psychology (PT 2023)*, Hong Kong, China, 27–30 June 2023; pp. 7–30.
144. Fernández-Álvarez, J.; Di Lerna, D.; Riva, G. Virtual Reality for Anxiety Disorders: Rethinking a Field in Expansion. In *Anxiety Disorders: Rethinking and Understanding Recent Discoveries*; Springer: Berlin/Heidelberg, Germany, 2020; pp. 389–414.
145. Barker, K. Utilizing Virtual Reality Therapy in the Treatment of Generalized Anxiety Disorder in College Counseling Centers. Ph.D. Thesis, Eastern Kentucky University, Richmond, KY, USA, 2021; p. 60. Available online: https://encompass.eku.edu/psych_doctorals/13 (accessed on 4 December 2024).
146. Debs, A.H. A Study of Social Anxiety in Extended Reality Environments. Mater's Thesis, Dartmouth College, Hanover, NH, USA, 2024. Available online: https://digitalcommons.dartmouth.edu/masters_theses/137 (accessed on 4 December 2024).
147. Hilty, D.M.; Armstrong, C.M.; Smout, S.A.; Crawford, A.; Maheu, M.M.; Drude, K.P.; Chan, S.; Yellowlees, P.M.; Krupinski, E.A. Findings and guidelines on provider technology, fatigue, and well-being: Scoping review. *J. Med. Internet Res.* **2022**, *24*, e34451. [CrossRef] [PubMed]
148. Hirani, R.; Noruzi, K.; Khuram, H.; Hussaini, A.S.; Aifuwa, E.I.; Ely, K.E.; Lewis, J.M.; Gabr, A.E.; Smiley, A.; Tiwari, R.K. Artificial Intelligence and Healthcare: A Journey through History, Present Innovations, and Future Possibilities. *Life* **2024**, *14*, 557. [CrossRef]
149. Bikkasani, D.C. Navigating Artificial General Intelligence (AGI): Societal Implications, Ethical Considerations, and Governance Strategies. *AI Ethics* **2024**, *20*, 1–16. [CrossRef]
150. Rane, N.; Paramesha, M.; Rane, J.; Kaya, O. Emerging trends and future research opportunities in artificial intelligence, machine learning, and deep learning. *Artif. Intell. Ind. Soc.* **2024**, *5*, 95–118.
151. Mohr, D.C.; Riper, H.; Schueller, S.M. A solution-focused research approach to achieve an implementable revolution in digital mental health. *JAMA Psychiatry* **2018**, *75*, 113–114. [CrossRef]
152. Bruns, E.J.; Parker, E.M.; Hensley, S.; Pullmann, M.D.; Benjamin, P.H.; Lyon, A.R.; Hoagwood, K.E. The role of the outer setting in implementation: Associations between state demographic, fiscal, and policy factors and use of evidence-based treatments in mental healthcare. *Implement. Sci.* **2019**, *14*, 1–13. [CrossRef]
153. Char, D.S.; Shah, N.H.; Magnus, D. Implementing machine learning in health care—Addressing ethical challenges. *N. Engl. J. Med.* **2018**, *378*, 981–983. [CrossRef] [PubMed]

154. U.S. Food and Drug Administration (FDA). Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions. Available online: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence> (accessed on 4 December 2024).
155. Health Canada; U.S. Food and Drug Administration (FDA); United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles. Available online: <https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles> (accessed on 13 November 2024).
156. Abd-Alrazaq, A.A.; Alajlani, M.; Alalwan, A.A.; Bewick, B.M.; Gardner, P.; Househ, M. An overview of the features of chatbots in mental health: A scoping review. *Int. J. Med. Inform.* **2019**, *132*, 103978. [CrossRef] [PubMed]
157. Amann, J.; Blasimme, A.; Vayena, E.; Frey, D.; Madai, V.I.; Consortium, P.Q. Explainability for artificial intelligence in healthcare: A multidisciplinary perspective. *BMC Med. Inform. Decis. Mak.* **2020**, *20*, 1–9. [CrossRef]
158. Smuha, N.A. The EU approach to ethics guidelines for trustworthy artificial intelligence. *Comput. Law Rev. Int.* **2019**, *20*, 97–106. [CrossRef]
159. Smuha, N.A.; Ahmed-Rengers, E.; Harkens, A.; Li, W.; MacLaren, J.; Piselli, R.; Yeung, K. How the EU Can Achieve Legally Trustworthy AI: A Response to the European Commission’s Proposal for an Artificial Intelligence Act. *SSRN Electron. J.* **2021**, *64*. [CrossRef]
160. Masters, K. Artificial intelligence in medical education. *Med. Teach.* **2019**, *41*, 976–980. [CrossRef]
161. Fiske, A.; Henningsen, P.; Buyx, A. Your robot therapist will see you now: Ethical implications of embodied artificial intelligence in psychiatry, psychology, and psychotherapy. *J. Med. Internet Res.* **2019**, *21*, e13216. [CrossRef] [PubMed]
162. Dworschak, C.; Heim, E.; Maercker, A. Efficacy of internet-based interventions for common mental disorder symptoms and psychosocial problems in older adults: A systematic review and meta-analysis. *Internet Interv.* **2022**, *27*, 100498. [CrossRef] [PubMed]
163. Sin, J.; Galeazzi, G.; McGregor, E.; Collom, J.; Taylor, A.; Barrett, B.; Lawrence, V.; Henderson, C. Digital Interventions for Screening and Treating Common Mental Disorders or Symptoms of Common Mental Illness in Adults: Systematic Review and Meta-analysis. *J. Med. Internet Res.* **2020**, *22*, e20581. [CrossRef] [PubMed]
164. Merchant, R.; Torous, J.; Rodriguez-Villa, E.; Naslund, J.A. Digital technology for management of severe mental disorders in low-income and middle-income countries. *Curr. Opin. Psychiatry* **2020**, *33*, 501–507. [CrossRef]
165. Karyotaki, E.; Miguel, C.; Panagiotopoulou, O.M.; Harrer, M.; Seward, N.; Sijbrandij, M.; Araya, R.; Patel, V.; Cuijpers, P. Digital interventions for common mental disorders in low-and middle-income countries: A systematic review and meta-analysis. *Camb. Prisms Glob. Ment. Health* **2023**, *13*, 1–28. [CrossRef]
166. Guastello, S.J. *Human Factors Engineering and Ergonomics: A Systems Approach*; CRC Press: Boca Raton, FL, USA, 2023.
167. Lazar, J.; Feng, J.H.; Hochheiser, H. *Research Methods in Human-Computer Interaction*; Morgan Kaufmann: Burlington, MA, USA, 2017.
168. Balcombe, L. AI Chatbots in Digital Mental Health. *Informatics* **2023**, *10*, 82. [CrossRef]
169. Dinesh, D.N.; Rao, M.N.; Sinha, C. Language adaptations of mental health interventions: User interaction comparisons with an AI-enabled conversational agent (Wysa) in English and Spanish. *Digit. Health* **2024**, *10*, 20552076241255616. [CrossRef] [PubMed]
170. McStay, A. *Emotional AI: The Rise of Empathic Media*; Sage Publications: London, UK, 2018.
171. Szymoniak, S.; Kubanek, M. Ethical threats associated with the application of artificial intelligence: A comprehensive review. In Proceedings of the Smart Ethics in the Digital World: Proceedings of the ETHICOMP 2024 21th International Conference on the Ethical and Social Impacts of ICT, Logroño, Spain, 13–15 March 2024; pp. 221–224.
172. Adekunle, J.J.; Komguem, S.J.T.; Abah, V.E.; Monica, N.N. AI Ethics, Balancing Innovation and Accountability. *J. Syst. Mod. Sci. Res.* **2024**, *4*, 14.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.